NO314585B1 - Pyrazolpyrimidinoner som hemmer cyklisk guanosin-3',5'- monofosfatfosfodiesterase type 5 (cGMP PDE5), for behandling av seksuell dysfunksjon - Google Patents
Pyrazolpyrimidinoner som hemmer cyklisk guanosin-3',5'- monofosfatfosfodiesterase type 5 (cGMP PDE5), for behandling av seksuell dysfunksjon Download PDFInfo
- Publication number
- NO314585B1 NO314585B1 NO19995211A NO995211A NO314585B1 NO 314585 B1 NO314585 B1 NO 314585B1 NO 19995211 A NO19995211 A NO 19995211A NO 995211 A NO995211 A NO 995211A NO 314585 B1 NO314585 B1 NO 314585B1
- Authority
- NO
- Norway
- Prior art keywords
- preparation
- pyrimidin
- title compound
- pyrazolo
- dihydro
- Prior art date
Links
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 title claims description 20
- ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 title description 14
- 238000011282 treatment Methods 0.000 title description 6
- 230000002401 inhibitory effect Effects 0.000 title description 3
- RGTMHUKTLKJHNW-UHFFFAOYSA-N 1H-pyrazole 1H-pyrimidin-2-one Chemical class N1C(N=CC=C1)=O.N1N=CC=C1 RGTMHUKTLKJHNW-UHFFFAOYSA-N 0.000 title 1
- 101100189582 Dictyostelium discoideum pdeD gene Proteins 0.000 title 1
- 101150098694 PDE5A gene Proteins 0.000 title 1
- 201000001880 Sexual dysfunction Diseases 0.000 title 1
- 102000011016 Type 5 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 title 1
- 108010037581 Type 5 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 title 1
- 102100029175 cGMP-specific 3',5'-cyclic phosphodiesterase Human genes 0.000 title 1
- 231100000872 sexual dysfunction Toxicity 0.000 title 1
- 238000002360 preparation method Methods 0.000 claims description 486
- 150000001875 compounds Chemical class 0.000 claims description 430
- 238000000034 method Methods 0.000 claims description 239
- -1 1-oxidopyridinyl Chemical group 0.000 claims description 100
- 230000002829 reductive effect Effects 0.000 claims description 83
- 239000000203 mixture Substances 0.000 claims description 69
- 150000003839 salts Chemical class 0.000 claims description 45
- 239000012453 solvate Substances 0.000 claims description 29
- 229910052757 nitrogen Inorganic materials 0.000 claims description 26
- 239000000460 chlorine Substances 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 19
- 125000000623 heterocyclic group Chemical group 0.000 claims description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 13
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 12
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 12
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 12
- 125000004193 piperazinyl group Chemical group 0.000 claims description 12
- 125000001424 substituent group Chemical group 0.000 claims description 11
- 201000001068 Prinzmetal angina Diseases 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 125000001425 triazolyl group Chemical group 0.000 claims description 10
- 229910052736 halogen Inorganic materials 0.000 claims description 9
- 238000007363 ring formation reaction Methods 0.000 claims description 9
- 206010057671 Female sexual dysfunction Diseases 0.000 claims description 8
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 8
- 125000002883 imidazolyl group Chemical group 0.000 claims description 8
- 125000002757 morpholinyl group Chemical group 0.000 claims description 8
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 7
- 241001465754 Metazoa Species 0.000 claims description 7
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 claims description 7
- 238000009472 formulation Methods 0.000 claims description 7
- 150000002367 halogens Chemical class 0.000 claims description 7
- 201000001881 impotence Diseases 0.000 claims description 7
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 claims description 7
- 238000011321 prophylaxis Methods 0.000 claims description 7
- 201000001320 Atherosclerosis Diseases 0.000 claims description 6
- 206010071445 Bladder outlet obstruction Diseases 0.000 claims description 6
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 6
- 206010013935 Dysmenorrhoea Diseases 0.000 claims description 6
- 208000010412 Glaucoma Diseases 0.000 claims description 6
- 206010019280 Heart failures Diseases 0.000 claims description 6
- 206010020772 Hypertension Diseases 0.000 claims description 6
- 206010021639 Incontinence Diseases 0.000 claims description 6
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 6
- 206010036600 Premature labour Diseases 0.000 claims description 6
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 6
- 208000006011 Stroke Diseases 0.000 claims description 6
- 208000003800 Urinary Bladder Neck Obstruction Diseases 0.000 claims description 6
- 201000009961 allergic asthma Diseases 0.000 claims description 6
- 201000010105 allergic rhinitis Diseases 0.000 claims description 6
- 208000006673 asthma Diseases 0.000 claims description 6
- 206010006451 bronchitis Diseases 0.000 claims description 6
- 229910052801 chlorine Inorganic materials 0.000 claims description 6
- 208000023819 chronic asthma Diseases 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 230000008991 intestinal motility Effects 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 6
- 125000004076 pyridyl group Chemical group 0.000 claims description 6
- 206010002388 Angina unstable Diseases 0.000 claims description 5
- 208000007718 Stable Angina Diseases 0.000 claims description 5
- 208000007814 Unstable Angina Diseases 0.000 claims description 5
- 208000009325 Variant Angina Pectoris Diseases 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 238000009109 curative therapy Methods 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims description 5
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 5
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 5
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 5
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 5
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 5
- 125000000335 thiazolyl group Chemical group 0.000 claims description 5
- ZYHQGITXIJDDKC-UHFFFAOYSA-N 2-[2-(2-aminophenyl)ethyl]aniline Chemical group NC1=CC=CC=C1CCC1=CC=CC=C1N ZYHQGITXIJDDKC-UHFFFAOYSA-N 0.000 claims description 4
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims description 4
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 claims description 4
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims description 4
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 3
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 3
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 3
- 208000006399 Premature Obstetric Labor Diseases 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 230000017531 blood circulation Effects 0.000 claims description 3
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 3
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000003386 piperidinyl group Chemical group 0.000 claims description 3
- 208000026440 premature labor Diseases 0.000 claims description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 3
- 125000001607 1,2,3-triazol-1-yl group Chemical group [*]N1N=NC([H])=C1[H] 0.000 claims description 2
- 125000001766 1,2,4-oxadiazol-3-yl group Chemical group [H]C1=NC(*)=NO1 0.000 claims description 2
- 125000003626 1,2,4-triazol-1-yl group Chemical group [*]N1N=C([H])N=C1[H] 0.000 claims description 2
- DRIPPBPKPZJMRK-UHFFFAOYSA-N 1-[(1-methylimidazol-2-yl)methyl]-5-[5-(4-methylpiperazin-1-yl)sulfonyl-2-propoxyphenyl]-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCOC1=CC=C(S(=O)(=O)N2CCN(C)CC2)C=C1C(NC(=O)C=12)=NC=1C(CCC)=NN2CC1=NC=CN1C DRIPPBPKPZJMRK-UHFFFAOYSA-N 0.000 claims description 2
- NIBCDDKWFDEBEP-UHFFFAOYSA-N 3-ethyl-5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-propoxyphenyl]-2-(pyridin-2-ylmethyl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCOC1=CC=C(S(=O)(=O)N2CCN(CC)CC2)C=C1C(NC1=C2CC)=NC(=O)C1=NN2CC1=CC=CC=N1 NIBCDDKWFDEBEP-UHFFFAOYSA-N 0.000 claims description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims description 2
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- UYAYUQTWQGZTRW-UHFFFAOYSA-N 5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-propoxyphenyl]-3-propyl-2-(pyrazin-2-ylmethyl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCOC1=CC=C(S(=O)(=O)N2CCN(CC)CC2)C=C1C(NC(=O)C1=N2)=NC1=C(CCC)N2CC1=CN=CC=N1 UYAYUQTWQGZTRW-UHFFFAOYSA-N 0.000 claims description 2
- OQYWVCNPOTZBOU-UHFFFAOYSA-N 5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-propoxyphenyl]-3-propyl-2-(pyridazin-3-ylmethyl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCOC1=CC=C(S(=O)(=O)N2CCN(CC)CC2)C=C1C(NC(=O)C1=N2)=NC1=C(CCC)N2CC1=CC=CN=N1 OQYWVCNPOTZBOU-UHFFFAOYSA-N 0.000 claims description 2
- AFXWHZNUUIIFFR-UHFFFAOYSA-N 5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-propoxyphenyl]-3-propyl-2-(pyridin-2-ylmethyl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCOC1=CC=C(S(=O)(=O)N2CCN(CC)CC2)C=C1C(NC(=O)C1=N2)=NC1=C(CCC)N2CC1=CC=CC=N1 AFXWHZNUUIIFFR-UHFFFAOYSA-N 0.000 claims description 2
- ORWIHWJJQPOUJI-UHFFFAOYSA-N 5-[5-[4-(2-hydroxyethyl)piperazin-1-yl]sulfonyl-2-propoxyphenyl]-3-propyl-1-(pyridin-2-ylmethyl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCOC1=CC=C(S(=O)(=O)N2CCN(CCO)CC2)C=C1C(NC=1C(CCC)=N2)=NC(=O)C=1N2CC1=CC=CC=N1 ORWIHWJJQPOUJI-UHFFFAOYSA-N 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 claims description 2
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 claims description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 2
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 claims description 2
- 125000004353 pyrazol-1-yl group Chemical group [H]C1=NN(*)C([H])=C1[H] 0.000 claims description 2
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 claims description 2
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims description 2
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 230000035876 healing Effects 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 239000007787 solid Substances 0.000 description 169
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 144
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 137
- 239000000243 solution Substances 0.000 description 107
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 87
- 239000006260 foam Substances 0.000 description 73
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 55
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 53
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 52
- 239000011541 reaction mixture Substances 0.000 description 41
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 39
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 34
- 238000004440 column chromatography Methods 0.000 description 34
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 33
- 239000000741 silica gel Substances 0.000 description 33
- 229910002027 silica gel Inorganic materials 0.000 description 33
- WGCYRFWNGRMRJA-UHFFFAOYSA-N 1-ethylpiperazine Chemical compound CCN1CCNCC1 WGCYRFWNGRMRJA-UHFFFAOYSA-N 0.000 description 32
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 28
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 27
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 27
- 238000010992 reflux Methods 0.000 description 25
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 24
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 22
- 238000006243 chemical reaction Methods 0.000 description 21
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 21
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 20
- 239000002904 solvent Substances 0.000 description 20
- 239000000725 suspension Substances 0.000 description 19
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- 239000003480 eluent Substances 0.000 description 18
- 239000003921 oil Substances 0.000 description 18
- 235000019198 oils Nutrition 0.000 description 18
- WFCSWCVEJLETKA-UHFFFAOYSA-N 2-piperazin-1-ylethanol Chemical compound OCCN1CCNCC1 WFCSWCVEJLETKA-UHFFFAOYSA-N 0.000 description 17
- 239000011734 sodium Substances 0.000 description 17
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 17
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 16
- 239000012458 free base Substances 0.000 description 16
- 239000000284 extract Substances 0.000 description 15
- 239000000843 powder Substances 0.000 description 15
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 14
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 14
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 14
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 14
- 238000001816 cooling Methods 0.000 description 13
- 238000010828 elution Methods 0.000 description 13
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 12
- 239000008346 aqueous phase Substances 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 239000012074 organic phase Substances 0.000 description 12
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 12
- 238000002425 crystallisation Methods 0.000 description 11
- 230000008025 crystallization Effects 0.000 description 11
- 239000012258 stirred mixture Substances 0.000 description 11
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 10
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- 239000002585 base Substances 0.000 description 10
- 239000012267 brine Substances 0.000 description 10
- 239000000706 filtrate Substances 0.000 description 10
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 102100024085 Alpha-aminoadipic semialdehyde dehydrogenase Human genes 0.000 description 9
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 9
- 101710135349 Venom phosphodiesterase Proteins 0.000 description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 9
- NJWIMFZLESWFIM-UHFFFAOYSA-N 2-(chloromethyl)pyridine Chemical compound ClCC1=CC=CC=N1 NJWIMFZLESWFIM-UHFFFAOYSA-N 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 8
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 8
- 239000012043 crude product Substances 0.000 description 8
- 238000001914 filtration Methods 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 8
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical group CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 7
- 238000005804 alkylation reaction Methods 0.000 description 7
- 235000011114 ammonium hydroxide Nutrition 0.000 description 7
- 239000012230 colorless oil Substances 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- 230000029936 alkylation Effects 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 210000005226 corpus cavernosum Anatomy 0.000 description 5
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 4
- BMEMBBFDTYHTLH-UHFFFAOYSA-N 1-(2-methoxyethyl)piperazine Chemical compound COCCN1CCNCC1 BMEMBBFDTYHTLH-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 4
- WRKWQCNJAZPEKK-UHFFFAOYSA-N 5-methyl-1h-pyrazole-3-carboxamide Chemical compound CC=1C=C(C(N)=O)NN=1 WRKWQCNJAZPEKK-UHFFFAOYSA-N 0.000 description 4
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 4
- 239000007832 Na2SO4 Substances 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 150000001350 alkyl halides Chemical class 0.000 description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
- 229910000024 caesium carbonate Inorganic materials 0.000 description 4
- XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- 150000003512 tertiary amines Chemical class 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- RFFLAFLAYFXFSW-UHFFFAOYSA-N 1,2-dichlorobenzene Chemical group ClC1=CC=CC=C1Cl RFFLAFLAYFXFSW-UHFFFAOYSA-N 0.000 description 3
- YGKDISJLDVGNOR-UHFFFAOYSA-N 4-(chloromethyl)-2-methyl-1,3-thiazole;hydrochloride Chemical compound Cl.CC1=NC(CCl)=CS1 YGKDISJLDVGNOR-UHFFFAOYSA-N 0.000 description 3
- NIFAUKBQIAURIM-UHFFFAOYSA-N 4-(chloromethyl)-3,5-dimethyl-1,2-oxazole Chemical compound CC1=NOC(C)=C1CCl NIFAUKBQIAURIM-UHFFFAOYSA-N 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- 239000002841 Lewis acid Substances 0.000 description 3
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 150000001263 acyl chlorides Chemical class 0.000 description 3
- 150000004703 alkoxides Chemical class 0.000 description 3
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- JNODQFNWMXFMEV-UHFFFAOYSA-N latrepirdine Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CCC1=CC=C(C)N=C1 JNODQFNWMXFMEV-UHFFFAOYSA-N 0.000 description 3
- 150000007517 lewis acids Chemical class 0.000 description 3
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 3
- AEXITZJSLGALNH-UHFFFAOYSA-N n'-hydroxyethanimidamide Chemical compound CC(N)=NO AEXITZJSLGALNH-UHFFFAOYSA-N 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 235000011181 potassium carbonates Nutrition 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 238000005694 sulfonylation reaction Methods 0.000 description 3
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 239000011592 zinc chloride Substances 0.000 description 3
- 235000005074 zinc chloride Nutrition 0.000 description 3
- BXCBUWKTXLWPSB-UHFFFAOYSA-N 1-(chloromethyl)-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1CCl BXCBUWKTXLWPSB-UHFFFAOYSA-N 0.000 description 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
- IBYHHJPAARCAIE-UHFFFAOYSA-N 1-bromo-2-chloroethane Chemical compound ClCCBr IBYHHJPAARCAIE-UHFFFAOYSA-N 0.000 description 2
- JQZAEUFPPSRDOP-UHFFFAOYSA-N 1-chloro-4-(chloromethyl)benzene Chemical compound ClCC1=CC=C(Cl)C=C1 JQZAEUFPPSRDOP-UHFFFAOYSA-N 0.000 description 2
- JDIPKQBKSBWIKU-UHFFFAOYSA-N 2-(chloromethyl)-1-methylimidazole;hydrochloride Chemical compound Cl.CN1C=CN=C1CCl JDIPKQBKSBWIKU-UHFFFAOYSA-N 0.000 description 2
- GFHPSQFCHUIFTO-UHFFFAOYSA-N 2-(chloromethyl)pyrazine Chemical compound ClCC1=CN=CC=N1 GFHPSQFCHUIFTO-UHFFFAOYSA-N 0.000 description 2
- REXUYBKPWIPONM-UHFFFAOYSA-N 2-bromoacetonitrile Chemical compound BrCC#N REXUYBKPWIPONM-UHFFFAOYSA-N 0.000 description 2
- MDKAAWDKKBFSTK-UHFFFAOYSA-N 2-ethoxybenzoyl chloride Chemical compound CCOC1=CC=CC=C1C(Cl)=O MDKAAWDKKBFSTK-UHFFFAOYSA-N 0.000 description 2
- ASUDFOJKTJLAIK-UHFFFAOYSA-N 2-methoxyethanamine Chemical compound COCCN ASUDFOJKTJLAIK-UHFFFAOYSA-N 0.000 description 2
- QUZYRVVDVHPXBB-UHFFFAOYSA-N 2-methyl-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound N1C=NC(=O)C=2C1=C(CCC)N(C)N=2 QUZYRVVDVHPXBB-UHFFFAOYSA-N 0.000 description 2
- MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 description 2
- AQSRRZGQRFFFGS-UHFFFAOYSA-N 2-methylpyridin-3-ol Chemical compound CC1=NC=CC=C1O AQSRRZGQRFFFGS-UHFFFAOYSA-N 0.000 description 2
- VNRJGEMERJZKLQ-UHFFFAOYSA-N 2-piperazin-1-ylacetamide Chemical compound NC(=O)CN1CCNCC1 VNRJGEMERJZKLQ-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- NBJHDLKSWUDGJG-UHFFFAOYSA-N 4-(2-chloroethyl)morpholin-4-ium;chloride Chemical compound Cl.ClCCN1CCOCC1 NBJHDLKSWUDGJG-UHFFFAOYSA-N 0.000 description 2
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 2
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 2
- ZESCZOKYYXYNNQ-UHFFFAOYSA-N 5-(chloromethyl)-1-methyl-1,2,4-triazole;hydrochloride Chemical compound Cl.CN1N=CN=C1CCl ZESCZOKYYXYNNQ-UHFFFAOYSA-N 0.000 description 2
- 125000004070 6 membered heterocyclic group Chemical group 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229940124639 Selective inhibitor Drugs 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- JHVLLYQQQYIWKX-UHFFFAOYSA-N benzyl 2-bromoacetate Chemical compound BrCC(=O)OCC1=CC=CC=C1 JHVLLYQQQYIWKX-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- FKGIKRMZMCYOAL-UHFFFAOYSA-N cyclobutylmethyl methanesulfonate Chemical compound CS(=O)(=O)OCC1CCC1 FKGIKRMZMCYOAL-UHFFFAOYSA-N 0.000 description 2
- 239000012024 dehydrating agents Substances 0.000 description 2
- 239000002027 dichloromethane extract Substances 0.000 description 2
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 2
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 2
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- XWBDWHCCBGMXKG-UHFFFAOYSA-N ethanamine;hydron;chloride Chemical compound Cl.CCN XWBDWHCCBGMXKG-UHFFFAOYSA-N 0.000 description 2
- FCZCIXQGZOUIDN-UHFFFAOYSA-N ethyl 2-diethoxyphosphinothioyloxyacetate Chemical compound CCOC(=O)COP(=S)(OCC)OCC FCZCIXQGZOUIDN-UHFFFAOYSA-N 0.000 description 2
- 239000002024 ethyl acetate extract Substances 0.000 description 2
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000001640 fractional crystallisation Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 210000001308 heart ventricle Anatomy 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- UVGZZQFIUPSTIE-UHFFFAOYSA-N n-[6-(bromomethyl)pyridin-2-yl]-2,2-dimethylpropanamide Chemical compound CC(C)(C)C(=O)NC1=CC=CC(CBr)=N1 UVGZZQFIUPSTIE-UHFFFAOYSA-N 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- XITQUSLLOSKDTB-UHFFFAOYSA-N nitrofen Chemical compound C1=CC([N+](=O)[O-])=CC=C1OC1=CC=C(Cl)C=C1Cl XITQUSLLOSKDTB-UHFFFAOYSA-N 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 235000011007 phosphoric acid Nutrition 0.000 description 2
- 150000004885 piperazines Chemical class 0.000 description 2
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- DOTPSQVYOBAWPQ-UHFFFAOYSA-N pyrazolo[4,3-d]pyrimidin-3-one Chemical compound N1=CN=C2C(=O)N=NC2=C1 DOTPSQVYOBAWPQ-UHFFFAOYSA-N 0.000 description 2
- 239000013074 reference sample Substances 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
- 229940083618 sodium nitroprusside Drugs 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- FWPIDFUJEMBDLS-UHFFFAOYSA-L tin(II) chloride dihydrate Chemical compound O.O.Cl[Sn]Cl FWPIDFUJEMBDLS-UHFFFAOYSA-L 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- 238000001665 trituration Methods 0.000 description 2
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 1
- QAGATHCAVJHHGR-ZCFIWIBFSA-N (2r)-2-chloro-1-morpholin-4-ylpropan-1-one Chemical compound C[C@@H](Cl)C(=O)N1CCOCC1 QAGATHCAVJHHGR-ZCFIWIBFSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- GAWAYYRQGQZKCR-REOHCLBHSA-N (S)-2-chloropropanoic acid Chemical compound C[C@H](Cl)C(O)=O GAWAYYRQGQZKCR-REOHCLBHSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- YRIZYWQGELRKNT-UHFFFAOYSA-N 1,3,5-trichloro-1,3,5-triazinane-2,4,6-trione Chemical compound ClN1C(=O)N(Cl)C(=O)N(Cl)C1=O YRIZYWQGELRKNT-UHFFFAOYSA-N 0.000 description 1
- JFZSDNLQDTYVEE-UHFFFAOYSA-N 1,4-dihydropyrazolo[4,3-d]pyrimidin-7-one Chemical compound O=C1N=CNC2=C1NN=C2 JFZSDNLQDTYVEE-UHFFFAOYSA-N 0.000 description 1
- UBSIYQGXRKNEJP-UHFFFAOYSA-N 1-(2-chloroethyl)-1,2,4-triazole Chemical compound ClCCN1C=NC=N1 UBSIYQGXRKNEJP-UHFFFAOYSA-N 0.000 description 1
- FHDYRFNCTJFNQX-UHFFFAOYSA-N 1-(2-chloroethyl)-4-methylpiperazine Chemical compound CN1CCN(CCCl)CC1 FHDYRFNCTJFNQX-UHFFFAOYSA-N 0.000 description 1
- HUZHIOQELFFZBM-UHFFFAOYSA-N 1-(2-chloroethyl)pyrazole Chemical compound ClCCN1C=CC=N1 HUZHIOQELFFZBM-UHFFFAOYSA-N 0.000 description 1
- NHZHGQPHZURUDH-UHFFFAOYSA-N 1-(2-chloroethyl)triazole Chemical compound ClCCN1C=CN=N1 NHZHGQPHZURUDH-UHFFFAOYSA-N 0.000 description 1
- VWKRETYHNRHOMT-UHFFFAOYSA-N 1-(2-methoxyethyl)-1,2,4-triazole Chemical compound COCCN1C=NC=N1 VWKRETYHNRHOMT-UHFFFAOYSA-N 0.000 description 1
- XITQZCSHIHGSDL-UHFFFAOYSA-N 1-(2-morpholin-4-yl-2-oxoethyl)-5-(2-propoxyphenyl)-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCOC1=CC=CC=C1C(NC1=O)=NC2=C1N(CC(=O)N1CCOCC1)N=C2CCC XITQZCSHIHGSDL-UHFFFAOYSA-N 0.000 description 1
- BPMIZTQIRIEFPM-UHFFFAOYSA-N 1-(2-morpholin-4-ylethyl)-5-(2-propoxyphenyl)-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCOC1=CC=CC=C1C(NC1=O)=NC2=C1N(CCN1CCOCC1)N=C2CCC BPMIZTQIRIEFPM-UHFFFAOYSA-N 0.000 description 1
- ONYAKXNUGHWTOO-UHFFFAOYSA-N 1-(3,5-dimethyl-1,2-oxazol-4-yl)-5-(2-ethoxyphenyl)-3,6-dimethylpyrazolo[4,3-d]pyrimidin-7-one Chemical compound C(C)OC1=C(C=CC=C1)C=1N(C(C2=C(N=1)C(=NN2C=1C(=NOC=1C)C)C)=O)C ONYAKXNUGHWTOO-UHFFFAOYSA-N 0.000 description 1
- VTBOTOBFGSVRMA-UHFFFAOYSA-N 1-Methylcyclohexanol Chemical compound CC1(O)CCCCC1 VTBOTOBFGSVRMA-UHFFFAOYSA-N 0.000 description 1
- QMHLWASNJKHITH-UHFFFAOYSA-N 1-[(2-aminophenyl)methyl]-5-[2-ethoxy-5-(4-methylpiperazin-1-yl)sulfonylphenyl]-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound N1=C(C=2C(=CC=C(C=2)S(=O)(=O)N2CCN(C)CC2)OCC)NC(=O)C2=C1C(CCC)=NN2CC1=CC=CC=C1N QMHLWASNJKHITH-UHFFFAOYSA-N 0.000 description 1
- OUBLORLFMYVCTQ-UHFFFAOYSA-N 1-[(2-aminophenyl)methyl]-5-[5-[4-[2-[tert-butyl(dimethyl)silyl]oxyethyl]piperazin-1-yl]sulfonyl-2-propoxyphenyl]-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCOC1=CC=C(S(=O)(=O)N2CCN(CCO[Si](C)(C)C(C)(C)C)CC2)C=C1C(NC=1C(CCC)=N2)=NC(=O)C=1N2CC1=CC=CC=C1N OUBLORLFMYVCTQ-UHFFFAOYSA-N 0.000 description 1
- BZBOUGDPCUIVHC-UHFFFAOYSA-N 1-[(2-nitrophenyl)methyl]-5-(2-propoxyphenyl)-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCOC1=CC=CC=C1C(NC1=O)=NC2=C1N(CC=1C(=CC=CC=1)[N+]([O-])=O)N=C2CCC BZBOUGDPCUIVHC-UHFFFAOYSA-N 0.000 description 1
- YYKVFBDFFDWQSS-UHFFFAOYSA-N 1-[(3,5-dimethyl-1,2-oxazol-4-yl)methyl]-5-[5-(4-methylpiperazin-1-yl)sulfonyl-2-propoxyphenyl]-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCOC1=CC=C(S(=O)(=O)N2CCN(C)CC2)C=C1C(NC(=O)C=12)=NC=1C(CCC)=NN2CC=1C(C)=NOC=1C YYKVFBDFFDWQSS-UHFFFAOYSA-N 0.000 description 1
- INYNGFYZRGTRPG-UHFFFAOYSA-N 1-[(3,5-dimethyl-1,2-oxazol-4-yl)methyl]-5-[5-[4-(2-hydroxyethyl)piperazin-1-yl]sulfonyl-2-propoxyphenyl]-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCOC1=CC=C(S(=O)(=O)N2CCN(CCO)CC2)C=C1C(NC(=O)C=12)=NC=1C(CCC)=NN2CC=1C(C)=NOC=1C INYNGFYZRGTRPG-UHFFFAOYSA-N 0.000 description 1
- XNYAJUOHASNNHA-UHFFFAOYSA-N 1-[(4-aminophenyl)methyl]-5-[2-ethoxy-5-(4-methylpiperazin-1-yl)sulfonylphenyl]-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound N1=C(C=2C(=CC=C(C=2)S(=O)(=O)N2CCN(C)CC2)OCC)NC(=O)C2=C1C(CCC)=NN2CC1=CC=C(N)C=C1 XNYAJUOHASNNHA-UHFFFAOYSA-N 0.000 description 1
- IAWWQOZFDQFCQP-UHFFFAOYSA-N 1-[(4-chlorophenyl)methyl]-5-(2-ethoxyphenyl)-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound N1=C(C=2C(=CC=CC=2)OCC)NC(=O)C2=C1C(CCC)=NN2CC1=CC=C(Cl)C=C1 IAWWQOZFDQFCQP-UHFFFAOYSA-N 0.000 description 1
- YBEOVQHJMIPARY-UHFFFAOYSA-N 1-[(4-chlorophenyl)methyl]-5-(2-propoxyphenyl)-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCOC1=CC=CC=C1C(NC1=O)=NC2=C1N(CC=1C=CC(Cl)=CC=1)N=C2CCC YBEOVQHJMIPARY-UHFFFAOYSA-N 0.000 description 1
- IWCHCWVTOHWESK-UHFFFAOYSA-N 1-[(4-chlorophenyl)methyl]-5-[2-ethoxy-5-[4-(2-hydroxyethyl)piperazin-1-yl]sulfonylphenyl]-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound N1=C(C=2C(=CC=C(C=2)S(=O)(=O)N2CCN(CCO)CC2)OCC)NC(=O)C2=C1C(CCC)=NN2CC1=CC=C(Cl)C=C1 IWCHCWVTOHWESK-UHFFFAOYSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- BSIIGUGKOPPTPZ-UHFFFAOYSA-N 1-bromo-4-(chloromethyl)benzene Chemical compound ClCC1=CC=C(Br)C=C1 BSIIGUGKOPPTPZ-UHFFFAOYSA-N 0.000 description 1
- PWKNBLFSJAVFAB-UHFFFAOYSA-N 1-fluoro-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1F PWKNBLFSJAVFAB-UHFFFAOYSA-N 0.000 description 1
- WFQDTOYDVUWQMS-UHFFFAOYSA-N 1-fluoro-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C=C1 WFQDTOYDVUWQMS-UHFFFAOYSA-N 0.000 description 1
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
- CWLUFVAFWWNXJZ-UHFFFAOYSA-N 1-hydroxypyrrolidine Chemical compound ON1CCCC1 CWLUFVAFWWNXJZ-UHFFFAOYSA-N 0.000 description 1
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- VLOODHWTRPYFIS-UHFFFAOYSA-N 2,4-dichloro-5-(chloromethyl)pyrimidine Chemical compound ClCC1=CN=C(Cl)N=C1Cl VLOODHWTRPYFIS-UHFFFAOYSA-N 0.000 description 1
- FTQMFESCASGQPS-UHFFFAOYSA-N 2-(2-aminophenyl)-5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-propoxyphenyl]-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCOC1=CC=C(S(=O)(=O)N2CCN(CC)CC2)C=C1C(NC(=O)C1=N2)=NC1=C(CCC)N2C1=CC=CC=C1N FTQMFESCASGQPS-UHFFFAOYSA-N 0.000 description 1
- LRIXKEQGKQFQAO-UHFFFAOYSA-N 2-(2-methoxyethoxy)benzoic acid Chemical compound COCCOC1=CC=CC=C1C(O)=O LRIXKEQGKQFQAO-UHFFFAOYSA-N 0.000 description 1
- WKJMJCQJCFVAOH-UHFFFAOYSA-N 2-(2-morpholin-4-yl-2-oxoethyl)-5-(2-propoxyphenyl)-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCOC1=CC=CC=C1C(NC(=O)C1=N2)=NC1=C(CCC)N2CC(=O)N1CCOCC1 WKJMJCQJCFVAOH-UHFFFAOYSA-N 0.000 description 1
- JJELSGOIASPRDT-UHFFFAOYSA-N 2-(2-morpholin-4-ylethyl)-5-(2-propoxyphenyl)-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCOC1=CC=CC=C1C(NC(=O)C1=N2)=NC1=C(CCC)N2CCN1CCOCC1 JJELSGOIASPRDT-UHFFFAOYSA-N 0.000 description 1
- BBUXZSBYFVUPLA-UHFFFAOYSA-N 2-(2-nitrophenyl)-5-(2-propoxyphenyl)-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCOC1=CC=CC=C1C1=NC2=C(CCC)N(C=3C(=CC=CC=3)[N+]([O-])=O)N=C2C(=O)N1 BBUXZSBYFVUPLA-UHFFFAOYSA-N 0.000 description 1
- NJBVVTDBKXQITG-UHFFFAOYSA-N 2-(3-methoxypyridin-2-yl)-6-methyl-5-(2-propoxyphenyl)-3-propylpyrazolo[4,3-d]pyrimidin-7-one Chemical compound COC=1C(=NC=CC=1)N1N=C2C(N=C(N(C2=O)C)C2=C(C=CC=C2)OCCC)=C1CCC NJBVVTDBKXQITG-UHFFFAOYSA-N 0.000 description 1
- GEJAYGKSIRWASM-UHFFFAOYSA-N 2-(4-aminophenyl)-5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-propoxyphenyl]-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCOC1=CC=C(S(=O)(=O)N2CCN(CC)CC2)C=C1C(NC(=O)C1=N2)=NC1=C(CCC)N2C1=CC=C(N)C=C1 GEJAYGKSIRWASM-UHFFFAOYSA-N 0.000 description 1
- AVGJCNHZIAHKOD-UHFFFAOYSA-N 2-(4-aminophenyl)-5-[5-(4-methylpiperazin-1-yl)sulfonyl-2-propoxyphenyl]-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCOC1=CC=C(S(=O)(=O)N2CCN(C)CC2)C=C1C(NC(=O)C1=N2)=NC1=C(CCC)N2C1=CC=C(N)C=C1 AVGJCNHZIAHKOD-UHFFFAOYSA-N 0.000 description 1
- ZQEWPOGUKMRWLT-UHFFFAOYSA-N 2-(4-nitrophenyl)-5-(2-propoxyphenyl)-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCOC1=CC=CC=C1C1=NC2=C(CCC)N(C=3C=CC(=CC=3)[N+]([O-])=O)N=C2C(=O)N1 ZQEWPOGUKMRWLT-UHFFFAOYSA-N 0.000 description 1
- QGXNHCXKWFNKCG-UHFFFAOYSA-N 2-(bromomethyl)benzonitrile Chemical compound BrCC1=CC=CC=C1C#N QGXNHCXKWFNKCG-UHFFFAOYSA-N 0.000 description 1
- VZKZHXJRVKNPGJ-UHFFFAOYSA-N 2-(chloromethyl)-3-methoxypyridine Chemical compound COC1=CC=CN=C1CCl VZKZHXJRVKNPGJ-UHFFFAOYSA-N 0.000 description 1
- JPMRGPPMXHGKRO-UHFFFAOYSA-N 2-(chloromethyl)pyridine hydrochloride Chemical compound Cl.ClCC1=CC=CC=N1 JPMRGPPMXHGKRO-UHFFFAOYSA-N 0.000 description 1
- SAGYKDQZIICODN-UHFFFAOYSA-N 2-(cyclobutylmethyl)-5-(2-ethoxyphenyl)-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound N1=C(C(NC(=N2)C=3C(=CC=CC=3)OCC)=O)C2=C(CCC)N1CC1CCC1 SAGYKDQZIICODN-UHFFFAOYSA-N 0.000 description 1
- PNKJROUMMQGOMO-UHFFFAOYSA-N 2-(cyclobutylmethyl)-5-(2-propoxyphenyl)-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCOC1=CC=CC=C1C(NC(=O)C1=N2)=NC1=C(CCC)N2CC1CCC1 PNKJROUMMQGOMO-UHFFFAOYSA-N 0.000 description 1
- MNLDAXGKINKFLE-UHFFFAOYSA-N 2-(cyclobutylmethyl)-5-[5-(4-methylpiperazin-1-yl)sulfonyl-2-propoxyphenyl]-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCOC1=CC=C(S(=O)(=O)N2CCN(C)CC2)C=C1C(NC(=O)C1=N2)=NC1=C(CCC)N2CC1CCC1 MNLDAXGKINKFLE-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- RKJNBMZNWYTQGX-UHFFFAOYSA-N 2-[(4-aminophenyl)methyl]-5-[2-ethoxy-5-(4-methylpiperazin-1-yl)sulfonylphenyl]-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound N1=C(C(NC(=N2)C=3C(=CC=C(C=3)S(=O)(=O)N3CCN(C)CC3)OCC)=O)C2=C(CCC)N1CC1=CC=C(N)C=C1 RKJNBMZNWYTQGX-UHFFFAOYSA-N 0.000 description 1
- RQZMBEJKOZICDT-UHFFFAOYSA-N 2-[(4-bromophenyl)methyl]-5-(2-ethoxyphenyl)-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound N1=C(C(NC(=N2)C=3C(=CC=CC=3)OCC)=O)C2=C(CCC)N1CC1=CC=C(Br)C=C1 RQZMBEJKOZICDT-UHFFFAOYSA-N 0.000 description 1
- KVRSFWMXZJCLFT-UHFFFAOYSA-N 2-[(4-bromophenyl)methyl]-5-[2-ethoxy-5-(4-methylpiperazin-1-yl)sulfonylphenyl]-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound N1=C(C(NC(=N2)C=3C(=CC=C(C=3)S(=O)(=O)N3CCN(C)CC3)OCC)=O)C2=C(CCC)N1CC1=CC=C(Br)C=C1 KVRSFWMXZJCLFT-UHFFFAOYSA-N 0.000 description 1
- BWIOJIUEQMFVSS-UHFFFAOYSA-N 2-[(4-bromophenyl)methyl]-5-[2-ethoxy-5-[4-(2-hydroxyethyl)piperazin-1-yl]sulfonylphenyl]-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound N1=C(C(NC(=N2)C=3C(=CC=C(C=3)S(=O)(=O)N3CCN(CCO)CC3)OCC)=O)C2=C(CCC)N1CC1=CC=C(Br)C=C1 BWIOJIUEQMFVSS-UHFFFAOYSA-N 0.000 description 1
- PIJROURAFSCUJY-UHFFFAOYSA-N 2-[(6-aminopyridin-2-yl)methyl]-5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-propoxyphenyl]-3-propyl-3,4-dihydro-1h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCOC1=CC=C(S(=O)(=O)N2CCN(CC)CC2)C=C1C(NC(=O)C=1N2)=NC=1C(CCC)N2CC1=CC=CC(N)=N1 PIJROURAFSCUJY-UHFFFAOYSA-N 0.000 description 1
- WLOBFDVJINWJPQ-UHFFFAOYSA-N 2-[2-(4-methylpiperazin-1-yl)ethyl]-5-[5-(4-methylpiperazin-1-yl)sulfonyl-2-propoxyphenyl]-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCOC1=CC=C(S(=O)(=O)N2CCN(C)CC2)C=C1C(NC(=O)C1=N2)=NC1=C(CCC)N2CCN1CCN(C)CC1 WLOBFDVJINWJPQ-UHFFFAOYSA-N 0.000 description 1
- IUPLTXNNRLZMNX-UHFFFAOYSA-N 2-[5-(2-ethoxyphenyl)-7-oxo-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-2-yl]acetonitrile Chemical compound CCCC=1N(CC#N)N=C(C(N2)=O)C=1N=C2C1=CC=CC=C1OCC IUPLTXNNRLZMNX-UHFFFAOYSA-N 0.000 description 1
- QNVCDXGOQWCRBH-UHFFFAOYSA-N 2-[7-oxo-5-(2-propoxyphenyl)-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-2-yl]acetic acid Chemical compound CCCOC1=CC=CC=C1C1=NC2=C(CCC)N(CC(O)=O)N=C2C(=O)N1 QNVCDXGOQWCRBH-UHFFFAOYSA-N 0.000 description 1
- NFKKEIQLHNLFAB-UHFFFAOYSA-N 2-[7-oxo-5-(2-propoxyphenyl)-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-2-yl]acetohydrazide;hydrochloride Chemical compound Cl.CCCOC1=CC=CC=C1C1=NC2=C(CCC)N(CC(=O)NN)N=C2C(=O)N1 NFKKEIQLHNLFAB-UHFFFAOYSA-N 0.000 description 1
- UNZDJCPYLBTMOR-UHFFFAOYSA-N 2-[7-oxo-5-(2-propoxyphenyl)-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-2-yl]acetonitrile Chemical compound CCCOC1=CC=CC=C1C1=NC2=C(CCC)N(CC#N)N=C2C(=O)N1 UNZDJCPYLBTMOR-UHFFFAOYSA-N 0.000 description 1
- YJRQQWIDBLFIGR-UHFFFAOYSA-N 2-[[5-(2-ethoxyphenyl)-7-oxo-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-1-yl]methyl]benzonitrile Chemical compound N1=C(C=2C(=CC=CC=2)OCC)NC(=O)C2=C1C(CCC)=NN2CC1=CC=CC=C1C#N YJRQQWIDBLFIGR-UHFFFAOYSA-N 0.000 description 1
- WGGPMGJVURLXFO-UHFFFAOYSA-N 2-[[5-[2-ethoxy-5-(4-methylpiperazin-1-yl)sulfonylphenyl]-7-oxo-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-1-yl]methyl]benzamide Chemical compound N1=C(C=2C(=CC=C(C=2)S(=O)(=O)N2CCN(C)CC2)OCC)NC(=O)C2=C1C(CCC)=NN2CC1=CC=CC=C1C(N)=O WGGPMGJVURLXFO-UHFFFAOYSA-N 0.000 description 1
- MYAGTLUXPAGIBN-UHFFFAOYSA-N 2-[[5-[2-ethoxy-5-(4-methylpiperazin-1-yl)sulfonylphenyl]-7-oxo-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-1-yl]methyl]benzonitrile Chemical compound N1=C(C=2C(=CC=C(C=2)S(=O)(=O)N2CCN(C)CC2)OCC)NC(=O)C2=C1C(CCC)=NN2CC1=CC=CC=C1C#N MYAGTLUXPAGIBN-UHFFFAOYSA-N 0.000 description 1
- GAWAYYRQGQZKCR-UHFFFAOYSA-N 2-chloropropionic acid Chemical compound CC(Cl)C(O)=O GAWAYYRQGQZKCR-UHFFFAOYSA-N 0.000 description 1
- UNCQVRBWJWWJBF-UHFFFAOYSA-N 2-chloropyrimidine Chemical compound ClC1=NC=CC=N1 UNCQVRBWJWWJBF-UHFFFAOYSA-N 0.000 description 1
- TXKSEEXWAGLOIY-UHFFFAOYSA-N 2-ethoxy-5-(4-methylpiperazin-1-yl)sulfonylbenzoic acid Chemical compound C1=C(C(O)=O)C(OCC)=CC=C1S(=O)(=O)N1CCN(C)CC1 TXKSEEXWAGLOIY-UHFFFAOYSA-N 0.000 description 1
- XDZMPRGFOOFSBL-UHFFFAOYSA-N 2-ethoxybenzoic acid Chemical compound CCOC1=CC=CC=C1C(O)=O XDZMPRGFOOFSBL-UHFFFAOYSA-N 0.000 description 1
- RZNHSEZOLFEFGB-UHFFFAOYSA-N 2-methoxybenzoyl chloride Chemical compound COC1=CC=CC=C1C(Cl)=O RZNHSEZOLFEFGB-UHFFFAOYSA-N 0.000 description 1
- OXOWWPXTTOCKKU-UHFFFAOYSA-N 2-propoxybenzoic acid Chemical compound CCCOC1=CC=CC=C1C(O)=O OXOWWPXTTOCKKU-UHFFFAOYSA-N 0.000 description 1
- BJMZHGBTBCQLNN-UHFFFAOYSA-N 2-propoxybenzoyl chloride Chemical compound CCCOC1=CC=CC=C1C(Cl)=O BJMZHGBTBCQLNN-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- CNYDPKJPMBRDPE-UHFFFAOYSA-N 3-(2-phenylethenyl)pyridazine Chemical compound C=1C=CC=CC=1C=CC1=CC=CN=N1 CNYDPKJPMBRDPE-UHFFFAOYSA-N 0.000 description 1
- YSNKGJCEHOJIDK-UHFFFAOYSA-N 3-(chloromethyl)-1,2,4-oxadiazole Chemical compound ClCC=1N=CON=1 YSNKGJCEHOJIDK-UHFFFAOYSA-N 0.000 description 1
- HJBQTICLMSHPDY-UHFFFAOYSA-N 3-(chloromethyl)-4-methyl-1,2,4-triazole;hydrochloride Chemical compound Cl.CN1C=NN=C1CCl HJBQTICLMSHPDY-UHFFFAOYSA-N 0.000 description 1
- LPKSYVXQAWQCSP-UHFFFAOYSA-N 3-(chloromethyl)pyridazine;hydrochloride Chemical compound Cl.ClCC1=CC=CN=N1 LPKSYVXQAWQCSP-UHFFFAOYSA-N 0.000 description 1
- CNQCWYFDIQSALX-UHFFFAOYSA-N 3-(chloromethyl)pyridine Chemical compound ClCC1=CC=CN=C1 CNQCWYFDIQSALX-UHFFFAOYSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- ZEKZHQZAKHLZQQ-UHFFFAOYSA-N 3-ethyl-5-(2-propoxyphenyl)-2,4-dihydropyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCOC1=CC=CC=C1C(NC1=O)=NC2=C1NN=C2CC ZEKZHQZAKHLZQQ-UHFFFAOYSA-N 0.000 description 1
- OABVKOFQXWSACK-UHFFFAOYSA-N 3-ethyl-5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-propoxyphenyl]-6-methyl-2-pyridin-2-ylpyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCOC1=CC=C(S(=O)(=O)N2CCN(CC)CC2)C=C1C(N(C(=O)C1=N2)C)=NC1=C(CC)N2C1=CC=CC=N1 OABVKOFQXWSACK-UHFFFAOYSA-N 0.000 description 1
- QRCUQLANPHYVEH-UHFFFAOYSA-N 3-methoxy-2-methylpyridine Chemical compound COC1=CC=CN=C1C QRCUQLANPHYVEH-UHFFFAOYSA-N 0.000 description 1
- MXDRPNGTQDRKQM-UHFFFAOYSA-N 3-methylpyridazine Chemical compound CC1=CC=CN=N1 MXDRPNGTQDRKQM-UHFFFAOYSA-N 0.000 description 1
- WHUUTUUXTSPPDS-UHFFFAOYSA-N 4-(2-phenylethenyl)pyridazine Chemical compound C=1C=CC=CC=1C=CC1=CC=NN=C1 WHUUTUUXTSPPDS-UHFFFAOYSA-N 0.000 description 1
- IQRWJYZHFFPIKP-UHFFFAOYSA-N 4-(2-phenylethenyl)pyrimidine Chemical compound C=1C=CC=CC=1C=CC1=CC=NC=N1 IQRWJYZHFFPIKP-UHFFFAOYSA-N 0.000 description 1
- KXODOFITUJNMKA-UHFFFAOYSA-N 4-(bromomethyl)benzamide Chemical compound NC(=O)C1=CC=C(CBr)C=C1 KXODOFITUJNMKA-UHFFFAOYSA-N 0.000 description 1
- OVILZFVTUVWJTO-UHFFFAOYSA-N 4-(chloromethyl)benzamide Chemical compound NC(=O)C1=CC=C(CCl)C=C1 OVILZFVTUVWJTO-UHFFFAOYSA-N 0.000 description 1
- BSXHSFRFTTYXOI-UHFFFAOYSA-N 4-(chloromethyl)benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=C(CCl)C=C1 BSXHSFRFTTYXOI-UHFFFAOYSA-N 0.000 description 1
- GQCWZBRWSGIKDK-UHFFFAOYSA-N 4-[(2-ethoxybenzoyl)amino]-5-methyl-1h-pyrazole-3-carboxamide Chemical compound CCOC1=CC=CC=C1C(=O)NC1=C(C(N)=O)NN=C1C GQCWZBRWSGIKDK-UHFFFAOYSA-N 0.000 description 1
- HHLIJPUCDKECCR-UHFFFAOYSA-N 4-[(2-ethoxybenzoyl)amino]-5-propyl-1h-pyrazole-3-carboxamide Chemical compound CCCC1=NNC(C(N)=O)=C1NC(=O)C1=CC=CC=C1OCC HHLIJPUCDKECCR-UHFFFAOYSA-N 0.000 description 1
- GXROBPAQTZBSMI-UHFFFAOYSA-N 4-[(2-methoxybenzoyl)amino]-5-propyl-1h-pyrazole-3-carboxamide Chemical compound CCCC1=NNC(C(N)=O)=C1NC(=O)C1=CC=CC=C1OC GXROBPAQTZBSMI-UHFFFAOYSA-N 0.000 description 1
- HYIVQBPSMWHYAG-UHFFFAOYSA-N 4-[(2-propoxybenzoyl)amino]-5-propyl-1h-pyrazole-3-carboxamide Chemical compound CCCOC1=CC=CC=C1C(=O)NC1=C(C(N)=O)NN=C1CCC HYIVQBPSMWHYAG-UHFFFAOYSA-N 0.000 description 1
- VXEGSRKPIUDPQT-UHFFFAOYSA-N 4-[4-(4-methoxyphenyl)piperazin-1-yl]aniline Chemical compound C1=CC(OC)=CC=C1N1CCN(C=2C=CC(N)=CC=2)CC1 VXEGSRKPIUDPQT-UHFFFAOYSA-N 0.000 description 1
- WKQYKEHODGZOOC-UHFFFAOYSA-N 4-[[5-(2-ethoxyphenyl)-7-oxo-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-1-yl]methyl]benzenesulfonamide Chemical compound N1=C(C=2C(=CC=CC=2)OCC)NC(=O)C2=C1C(CCC)=NN2CC1=CC=C(S(N)(=O)=O)C=C1 WKQYKEHODGZOOC-UHFFFAOYSA-N 0.000 description 1
- OIAMMOWRCJBWDW-UHFFFAOYSA-N 4-[[5-(2-ethoxyphenyl)-7-oxo-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-2-yl]methyl]benzamide Chemical compound N1=C(C(NC(=N2)C=3C(=CC=CC=3)OCC)=O)C2=C(CCC)N1CC1=CC=C(C(N)=O)C=C1 OIAMMOWRCJBWDW-UHFFFAOYSA-N 0.000 description 1
- HGQPYVJGNQUHNI-UHFFFAOYSA-N 4-[[5-[2-ethoxy-5-(4-methylpiperazin-1-yl)sulfonylphenyl]-7-oxo-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-1-yl]methyl]benzamide Chemical compound N1=C(C=2C(=CC=C(C=2)S(=O)(=O)N2CCN(C)CC2)OCC)NC(=O)C2=C1C(CCC)=NN2CC1=CC=C(C(N)=O)C=C1 HGQPYVJGNQUHNI-UHFFFAOYSA-N 0.000 description 1
- IBHTZQCWCQEQCW-UHFFFAOYSA-N 4-[[5-[2-ethoxy-5-(4-methylpiperazin-1-yl)sulfonylphenyl]-7-oxo-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-1-yl]methyl]benzenesulfonamide Chemical compound N1=C(C=2C(=CC=C(C=2)S(=O)(=O)N2CCN(C)CC2)OCC)NC(=O)C2=C1C(CCC)=NN2CC1=CC=C(S(N)(=O)=O)C=C1 IBHTZQCWCQEQCW-UHFFFAOYSA-N 0.000 description 1
- BSUKWJRBLTYQIK-UHFFFAOYSA-N 4-[[5-[2-ethoxy-5-(4-methylpiperazin-1-yl)sulfonylphenyl]-7-oxo-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-2-yl]methyl]benzamide Chemical compound N1=C(C(NC(=N2)C=3C(=CC=C(C=3)S(=O)(=O)N3CCN(C)CC3)OCC)=O)C2=C(CCC)N1CC1=CC=C(C(N)=O)C=C1 BSUKWJRBLTYQIK-UHFFFAOYSA-N 0.000 description 1
- JVXDFTZWKFHULK-UHFFFAOYSA-N 4-amino-1h-pyrazole-5-carboxamide Chemical class NC(=O)C=1NN=CC=1N JVXDFTZWKFHULK-UHFFFAOYSA-N 0.000 description 1
- MJDUUMJXEUAPET-UHFFFAOYSA-N 4-amino-2-benzyl-5-propylpyrazole-3-carboxamide Chemical compound NC(=O)C1=C(N)C(CCC)=NN1CC1=CC=CC=C1 MJDUUMJXEUAPET-UHFFFAOYSA-N 0.000 description 1
- YIAXJRMRAWYVOG-UHFFFAOYSA-N 4-amino-5-ethyl-1h-pyrazole-3-carboxamide Chemical compound CCC=1NN=C(C(N)=O)C=1N YIAXJRMRAWYVOG-UHFFFAOYSA-N 0.000 description 1
- DJMPBOHREJSJTB-UHFFFAOYSA-N 4-amino-5-methyl-1h-pyrazole-3-carboxamide Chemical compound CC=1NN=C(C(N)=O)C=1N DJMPBOHREJSJTB-UHFFFAOYSA-N 0.000 description 1
- ZYUBHFQBCBGCTP-UHFFFAOYSA-N 4-amino-5-propyl-1h-pyrazole-3-carboxamide Chemical compound CCCC1=NNC(C(N)=O)=C1N ZYUBHFQBCBGCTP-UHFFFAOYSA-N 0.000 description 1
- AIKUBOPKWKZULG-UHFFFAOYSA-N 4-methylpyridazine Chemical compound CC1=CC=NN=C1 AIKUBOPKWKZULG-UHFFFAOYSA-N 0.000 description 1
- LVILGAOSPDLNRM-UHFFFAOYSA-N 4-methylpyrimidine Chemical compound CC1=CC=NC=N1 LVILGAOSPDLNRM-UHFFFAOYSA-N 0.000 description 1
- OEOQYHINYSQQOO-UHFFFAOYSA-N 4-nitro-5-propyl-1h-pyrazole-3-carboxamide Chemical compound CCCC1=NNC(C(N)=O)=C1[N+]([O-])=O OEOQYHINYSQQOO-UHFFFAOYSA-N 0.000 description 1
- WTLTYNIWFANVBQ-UHFFFAOYSA-N 4-nitro-5-propyl-1h-pyrazole-3-carboxylic acid Chemical compound CCCC=1NN=C(C(O)=O)C=1[N+]([O-])=O WTLTYNIWFANVBQ-UHFFFAOYSA-N 0.000 description 1
- VOLRSQPSJGXRNJ-UHFFFAOYSA-N 4-nitrobenzyl bromide Chemical compound [O-][N+](=O)C1=CC=C(CBr)C=C1 VOLRSQPSJGXRNJ-UHFFFAOYSA-N 0.000 description 1
- WEZJVUPHWZBKKR-UHFFFAOYSA-N 5-(2-ethoxyphenyl)-1-[(4-nitrophenyl)methyl]-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound N1=C(C=2C(=CC=CC=2)OCC)NC(=O)C2=C1C(CCC)=NN2CC1=CC=C([N+]([O-])=O)C=C1 WEZJVUPHWZBKKR-UHFFFAOYSA-N 0.000 description 1
- FNYZEEFOQCLZHJ-UHFFFAOYSA-N 5-(2-ethoxyphenyl)-2-[(4-nitrophenyl)methyl]-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound N1=C(C(NC(=N2)C=3C(=CC=CC=3)OCC)=O)C2=C(CCC)N1CC1=CC=C([N+]([O-])=O)C=C1 FNYZEEFOQCLZHJ-UHFFFAOYSA-N 0.000 description 1
- XORRNCPGMSIEIP-UHFFFAOYSA-N 5-(2-ethoxyphenyl)-3,6-dimethyl-2-(2-methyl-1,3-thiazol-4-yl)pyrazolo[4,3-d]pyrimidin-7-one Chemical compound C(C)OC1=C(C=CC=C1)C=1N(C(C=2C(N=1)=C(N(N=2)C=1N=C(SC=1)C)C)=O)C XORRNCPGMSIEIP-UHFFFAOYSA-N 0.000 description 1
- QVGVBYFEOWUDTK-UHFFFAOYSA-N 5-(2-ethoxyphenyl)-3-methyl-2,4-dihydropyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCOC1=CC=CC=C1C(NC1=O)=NC2=C1NN=C2C QVGVBYFEOWUDTK-UHFFFAOYSA-N 0.000 description 1
- LSJMCZVDVVSHJA-UHFFFAOYSA-N 5-(2-ethoxyphenyl)-3-propyl-2,4-dihydropyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCC1=NNC(C(N2)=O)=C1N=C2C1=CC=CC=C1OCC LSJMCZVDVVSHJA-UHFFFAOYSA-N 0.000 description 1
- ZLYUNUQRAFJNFG-UHFFFAOYSA-N 5-(2-methoxyphenyl)-3-propyl-1-(pyridin-2-ylmethyl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound N1=C(C=2C(=CC=CC=2)OC)NC(=O)C2=C1C(CCC)=NN2CC1=CC=CC=N1 ZLYUNUQRAFJNFG-UHFFFAOYSA-N 0.000 description 1
- PXJJBEDOMOGGNA-UHFFFAOYSA-N 5-(2-methoxyphenyl)-3-propyl-2,4-dihydropyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCC1=NNC(C(N2)=O)=C1N=C2C1=CC=CC=C1OC PXJJBEDOMOGGNA-UHFFFAOYSA-N 0.000 description 1
- ZOUNLOKELMNDFA-UHFFFAOYSA-N 5-(2-propoxyphenyl)-3-propyl-2,4-dihydropyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCOC1=CC=CC=C1C(NC1=O)=NC2=C1NN=C2CCC ZOUNLOKELMNDFA-UHFFFAOYSA-N 0.000 description 1
- QRNYWLUPCXGXKL-UHFFFAOYSA-N 5-(2-propoxyphenyl)-3-propyl-2-(2-pyrazol-1-ylethyl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCOC1=CC=CC=C1C(NC(=O)C1=N2)=NC1=C(CCC)N2CCN1N=CC=C1 QRNYWLUPCXGXKL-UHFFFAOYSA-N 0.000 description 1
- ZQWCRUMULGDGFZ-UHFFFAOYSA-N 5-(2-propoxyphenyl)-3-propyl-2-(pyrazin-2-ylmethyl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCOC1=CC=CC=C1C(NC(=O)C1=N2)=NC1=C(CCC)N2CC1=CN=CC=N1 ZQWCRUMULGDGFZ-UHFFFAOYSA-N 0.000 description 1
- VXXZXIRZKFPSOF-UHFFFAOYSA-N 5-(2-propoxyphenyl)-3-propyl-2-(pyridin-2-ylmethyl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCOC1=CC=CC=C1C(NC(=O)C1=N2)=NC1=C(CCC)N2CC1=CC=CC=N1 VXXZXIRZKFPSOF-UHFFFAOYSA-N 0.000 description 1
- OOEFJEUBPNZBTO-UHFFFAOYSA-N 5-(2-propoxyphenyl)-3-propyl-2-(pyridin-3-ylmethyl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCOC1=CC=CC=C1C(NC(=O)C1=N2)=NC1=C(CCC)N2CC1=CC=CN=C1 OOEFJEUBPNZBTO-UHFFFAOYSA-N 0.000 description 1
- HCNAYYGHJAFBNV-UHFFFAOYSA-N 5-(2-propoxyphenyl)-3-propyl-2-[2-(1,2,4-triazol-1-yl)ethyl]-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCOC1=CC=CC=C1C(NC(=O)C1=N2)=NC1=C(CCC)N2CCN1N=CN=C1 HCNAYYGHJAFBNV-UHFFFAOYSA-N 0.000 description 1
- LNUBMUVFUZKVCM-UHFFFAOYSA-N 5-(2-propoxyphenyl)-3-propyl-2-[2-(triazol-1-yl)ethyl]-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCOC1=CC=CC=C1C(NC(=O)C1=N2)=NC1=C(CCC)N2CCN1N=NC=C1 LNUBMUVFUZKVCM-UHFFFAOYSA-N 0.000 description 1
- HJORJOCUBBXDEY-UHFFFAOYSA-N 5-(2-propoxyphenyl)-3-propyl-2-pyrimidin-2-yl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCOC1=CC=CC=C1C1=NC2=C(CCC)N(C=3N=CC=CN=3)N=C2C(=O)N1 HJORJOCUBBXDEY-UHFFFAOYSA-N 0.000 description 1
- GMRUUBABZXAQQF-UHFFFAOYSA-N 5-(4-ethylpiperazin-1-yl)sulfonyl-2-propoxybenzoic acid Chemical compound C1=C(C(O)=O)C(OCCC)=CC=C1S(=O)(=O)N1CCN(CC)CC1 GMRUUBABZXAQQF-UHFFFAOYSA-N 0.000 description 1
- LYPVHZLVCUVDKH-UHFFFAOYSA-N 5-(chloromethyl)-1-(2-methoxyethyl)-1,2,4-triazole;hydrochloride Chemical compound Cl.COCCN1N=CN=C1CCl LYPVHZLVCUVDKH-UHFFFAOYSA-N 0.000 description 1
- UOFYXQBJFHMRDU-UHFFFAOYSA-N 5-[2-ethoxy-5-(4-ethylpiperazin-1-yl)sulfonylphenyl]-3-propyl-2-(pyridin-2-ylmethyl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound N1=C(C(NC(=N2)C=3C(=CC=C(C=3)S(=O)(=O)N3CCN(CC)CC3)OCC)=O)C2=C(CCC)N1CC1=CC=CC=N1 UOFYXQBJFHMRDU-UHFFFAOYSA-N 0.000 description 1
- FMVRNIRUDQALPW-UHFFFAOYSA-N 5-[2-ethoxy-5-(4-ethylpiperazin-1-yl)sulfonylphenyl]-6-methyl-3-propyl-2-pyridin-2-ylpyrazolo[4,3-d]pyrimidin-7-one Chemical compound C(C)OC1=C(C=C(C=C1)S(=O)(=O)N1CCN(CC1)CC)C=1N(C(C=2C(N=1)=C(N(N=2)C1=NC=CC=C1)CCC)=O)C FMVRNIRUDQALPW-UHFFFAOYSA-N 0.000 description 1
- BERAECNLRAVXNG-UHFFFAOYSA-N 5-[2-ethoxy-5-(4-methylpiperazin-1-yl)sulfonylphenyl]-1-[(2-nitrophenyl)methyl]-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound N1=C(C=2C(=CC=C(C=2)S(=O)(=O)N2CCN(C)CC2)OCC)NC(=O)C2=C1C(CCC)=NN2CC1=CC=CC=C1[N+]([O-])=O BERAECNLRAVXNG-UHFFFAOYSA-N 0.000 description 1
- XPYMVLDCTGLAJF-UHFFFAOYSA-N 5-[2-ethoxy-5-(4-methylpiperazin-1-yl)sulfonylphenyl]-2-[(4-nitrophenyl)methyl]-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound N1=C(C(NC(=N2)C=3C(=CC=C(C=3)S(=O)(=O)N3CCN(C)CC3)OCC)=O)C2=C(CCC)N1CC1=CC=C([N+]([O-])=O)C=C1 XPYMVLDCTGLAJF-UHFFFAOYSA-N 0.000 description 1
- NABBIFYBCYNVLQ-UHFFFAOYSA-N 5-[2-ethoxy-5-[4-(2-hydroxyethyl)piperazin-1-yl]sulfonylphenyl]-2-[(4-nitrophenyl)methyl]-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound N1=C(C(NC(=N2)C=3C(=CC=C(C=3)S(=O)(=O)N3CCN(CCO)CC3)OCC)=O)C2=C(CCC)N1CC1=CC=C([N+]([O-])=O)C=C1 NABBIFYBCYNVLQ-UHFFFAOYSA-N 0.000 description 1
- YGBURXLJCXVONF-UHFFFAOYSA-N 5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-propoxyphenyl]-1-(2-morpholin-4-ylethyl)-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCOC1=CC=C(S(=O)(=O)N2CCN(CC)CC2)C=C1C(NC(=O)C=12)=NC=1C(CCC)=NN2CCN1CCOCC1 YGBURXLJCXVONF-UHFFFAOYSA-N 0.000 description 1
- VMVXNZARLRWIGX-UHFFFAOYSA-N 5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-propoxyphenyl]-2-(2-nitrophenyl)-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCOC1=CC=C(S(=O)(=O)N2CCN(CC)CC2)C=C1C(NC(=O)C1=N2)=NC1=C(CCC)N2C1=CC=CC=C1[N+]([O-])=O VMVXNZARLRWIGX-UHFFFAOYSA-N 0.000 description 1
- BGEJZWPJWRYHFC-UHFFFAOYSA-N 5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-propoxyphenyl]-2-(4-nitrophenyl)-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCOC1=CC=C(S(=O)(=O)N2CCN(CC)CC2)C=C1C(NC(=O)C1=N2)=NC1=C(CCC)N2C1=CC=C([N+]([O-])=O)C=C1 BGEJZWPJWRYHFC-UHFFFAOYSA-N 0.000 description 1
- FEAZHGNANMNTOI-UHFFFAOYSA-N 5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-propoxyphenyl]-3-propyl-2-(2-pyrazol-1-ylethyl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCOC1=CC=C(S(=O)(=O)N2CCN(CC)CC2)C=C1C(NC(=O)C1=N2)=NC1=C(CCC)N2CCN1C=CC=N1 FEAZHGNANMNTOI-UHFFFAOYSA-N 0.000 description 1
- IPSKBALNRWRQGZ-UHFFFAOYSA-N 5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-propoxyphenyl]-3-propyl-2-[2-(1,2,4-triazol-1-yl)ethyl]-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCOC1=CC=C(S(=O)(=O)N2CCN(CC)CC2)C=C1C(NC(=O)C1=N2)=NC1=C(CCC)N2CCN1C=NC=N1 IPSKBALNRWRQGZ-UHFFFAOYSA-N 0.000 description 1
- MBXUNTDIWNKBEN-UHFFFAOYSA-N 5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-propoxyphenyl]-3-propyl-2-[2-(triazol-1-yl)ethyl]-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCOC1=CC=C(S(=O)(=O)N2CCN(CC)CC2)C=C1C(NC(=O)C1=N2)=NC1=C(CCC)N2CCN1C=CN=N1 MBXUNTDIWNKBEN-UHFFFAOYSA-N 0.000 description 1
- APWNEODRYUEYAZ-UHFFFAOYSA-N 5-[5-(4-methylpiperazin-1-yl)sulfonyl-2-propoxyphenyl]-1-(2-morpholin-4-ylethyl)-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCOC1=CC=C(S(=O)(=O)N2CCN(C)CC2)C=C1C(NC(=O)C=12)=NC=1C(CCC)=NN2CCN1CCOCC1 APWNEODRYUEYAZ-UHFFFAOYSA-N 0.000 description 1
- VPWDCKLBIWXCSL-UHFFFAOYSA-N 5-[5-(4-methylpiperazin-1-yl)sulfonyl-2-propoxyphenyl]-2-(2-morpholin-4-yl-2-oxoethyl)-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCOC1=CC=C(S(=O)(=O)N2CCN(C)CC2)C=C1C(NC(=O)C1=N2)=NC1=C(CCC)N2CC(=O)N1CCOCC1 VPWDCKLBIWXCSL-UHFFFAOYSA-N 0.000 description 1
- TUWSVDSAVLLLGM-UHFFFAOYSA-N 5-[5-(4-methylpiperazin-1-yl)sulfonyl-2-propoxyphenyl]-2-(2-morpholin-4-ylethyl)-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCOC1=CC=C(S(=O)(=O)N2CCN(C)CC2)C=C1C(NC(=O)C1=N2)=NC1=C(CCC)N2CCN1CCOCC1 TUWSVDSAVLLLGM-UHFFFAOYSA-N 0.000 description 1
- IUCKXFYAQSTMDN-UHFFFAOYSA-N 5-[5-(4-methylpiperazin-1-yl)sulfonyl-2-propoxyphenyl]-2-(4-nitrophenyl)-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCOC1=CC=C(S(=O)(=O)N2CCN(C)CC2)C=C1C(NC(=O)C1=N2)=NC1=C(CCC)N2C1=CC=C([N+]([O-])=O)C=C1 IUCKXFYAQSTMDN-UHFFFAOYSA-N 0.000 description 1
- NQPLCZJAFCQWFM-UHFFFAOYSA-N 5-[5-[4-(2-methoxyethyl)piperazin-1-yl]sulfonyl-2-propoxyphenyl]-1-(2-morpholin-4-ylethyl)-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCOC1=CC=C(S(=O)(=O)N2CCN(CCOC)CC2)C=C1C(NC(=O)C=12)=NC=1C(CCC)=NN2CCN1CCOCC1 NQPLCZJAFCQWFM-UHFFFAOYSA-N 0.000 description 1
- PBCGYQDEJHUWCU-UHFFFAOYSA-N 5-[5-[4-(2-methoxyethyl)piperazin-1-yl]sulfonyl-2-propoxyphenyl]-2-[(2-methyl-1,2,4-triazol-3-yl)methyl]-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCOC1=CC=C(S(=O)(=O)N2CCN(CCOC)CC2)C=C1C(NC(=O)C1=N2)=NC1=C(CCC)N2CC1=NC=NN1C PBCGYQDEJHUWCU-UHFFFAOYSA-N 0.000 description 1
- UHNRCKXZRULNSC-UHFFFAOYSA-N 5-chlorosulfonyl-2-ethoxybenzoic acid Chemical compound CCOC1=CC=C(S(Cl)(=O)=O)C=C1C(O)=O UHNRCKXZRULNSC-UHFFFAOYSA-N 0.000 description 1
- AEADPYSAWUEPDF-UHFFFAOYSA-N 5-chlorosulfonyl-2-propoxybenzoic acid Chemical compound CCCOC1=CC=C(S(Cl)(=O)=O)C=C1C(O)=O AEADPYSAWUEPDF-UHFFFAOYSA-N 0.000 description 1
- WCQYJWRMYFJLRQ-UHFFFAOYSA-N 5-ethyl-1h-pyrazole-3-carboxylic acid Chemical compound CCC1=CC(C(O)=O)=NN1 WCQYJWRMYFJLRQ-UHFFFAOYSA-N 0.000 description 1
- FUXWIGWVDXHJEA-UHFFFAOYSA-N 5-ethyl-4-[(2-propoxybenzoyl)amino]-1h-pyrazole-3-carboxamide Chemical compound CCCOC1=CC=CC=C1C(=O)NC1=C(C(N)=O)NN=C1CC FUXWIGWVDXHJEA-UHFFFAOYSA-N 0.000 description 1
- XTPUQGFKKAURLH-UHFFFAOYSA-N 5-ethyl-4-nitro-1h-pyrazole-3-carboxamide Chemical compound CCC=1NN=C(C(N)=O)C=1[N+]([O-])=O XTPUQGFKKAURLH-UHFFFAOYSA-N 0.000 description 1
- UDYWTLMYXXTHKR-UHFFFAOYSA-N 5-ethyl-4-nitro-1h-pyrazole-3-carboxylic acid Chemical compound CCC=1NN=C(C(O)=O)C=1[N+]([O-])=O UDYWTLMYXXTHKR-UHFFFAOYSA-N 0.000 description 1
- WXVLOIREJGHFAE-UHFFFAOYSA-N 5-ethyl-4-nitro-2-(pyridin-2-ylmethyl)pyrazole-3-carboxamide Chemical compound NC(=O)C1=C([N+]([O-])=O)C(CC)=NN1CC1=CC=CC=N1 WXVLOIREJGHFAE-UHFFFAOYSA-N 0.000 description 1
- QYPSYPPSHXDFLV-UHFFFAOYSA-N 5-propyl-1h-pyrazole-3-carboxylic acid Chemical compound CCCC1=CC(C(O)=O)=NN1 QYPSYPPSHXDFLV-UHFFFAOYSA-N 0.000 description 1
- CJJDLCFTTDQZMW-UHFFFAOYSA-N 6-methyl-1-(2-methyl-1,2,4-triazol-3-yl)-5-(2-propoxyphenyl)-3-propylpyrazolo[4,3-d]pyrimidin-7-one Chemical compound CN1N=CN=C1N1N=C(C=2N=C(N(C(C=21)=O)C)C1=C(C=CC=C1)OCCC)CCC CJJDLCFTTDQZMW-UHFFFAOYSA-N 0.000 description 1
- DZOUAVBUQUFSDH-UHFFFAOYSA-N 6-methyl-1-(2-methyl-1,3-thiazol-4-yl)-5-(2-propoxyphenyl)-3-propylpyrazolo[4,3-d]pyrimidin-7-one Chemical compound CC=1SC=C(N=1)N1N=C(C=2N=C(N(C(C=21)=O)C)C1=C(C=CC=C1)OCCC)CCC DZOUAVBUQUFSDH-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 229910015900 BF3 Inorganic materials 0.000 description 1
- OKSSINKFYDVAOF-UHFFFAOYSA-N C(C(C)(C)C)(=O)NC1=CC=CC(=N1)N1N=C(C=2N=C(N(C(C21)=O)C)C2=C(C=CC=C2)OCCC)CCC Chemical compound C(C(C)(C)C)(=O)NC1=CC=CC(=N1)N1N=C(C=2N=C(N(C(C21)=O)C)C2=C(C=CC=C2)OCCC)CCC OKSSINKFYDVAOF-UHFFFAOYSA-N 0.000 description 1
- UAEJAOPMQGXFHJ-UHFFFAOYSA-N C(C(C)(C)C)(=O)NC1=CC=CC(=N1)N1N=C2C(N=C(N(C2=O)C)C2=C(C=CC=C2)OCCC)=C1CCC Chemical compound C(C(C)(C)C)(=O)NC1=CC=CC(=N1)N1N=C2C(N=C(N(C2=O)C)C2=C(C=CC=C2)OCCC)=C1CCC UAEJAOPMQGXFHJ-UHFFFAOYSA-N 0.000 description 1
- JOBPKXNWONLLSR-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCN(CC1)S(=O)(=O)C=1C=CC(=C(C1)C=1N(C(C=2C(N1)=C(N(N2)C2=NC=CC=C2)CCC)=O)C)OCCC Chemical compound C(C)(C)(C)OC(=O)N1CCN(CC1)S(=O)(=O)C=1C=CC(=C(C1)C=1N(C(C=2C(N1)=C(N(N2)C2=NC=CC=C2)CCC)=O)C)OCCC JOBPKXNWONLLSR-UHFFFAOYSA-N 0.000 description 1
- NSRRGYHUQMVDLR-UHFFFAOYSA-N C(C)C1=NN(C2=C1N=C(N(C2=O)C)C2=C(C=CC=C2)OCCC)C2=NC=CC=C2 Chemical compound C(C)C1=NN(C2=C1N=C(N(C2=O)C)C2=C(C=CC=C2)OCCC)C2=NC=CC=C2 NSRRGYHUQMVDLR-UHFFFAOYSA-N 0.000 description 1
- IDBOMKWDSUDPHG-UHFFFAOYSA-N C(C)C=1N(N=C2C1N=C(N(C2=O)C)C2=C(C=CC(=C2)S(=O)(=O)N2CCN(CC2)C)OCCC)C2=NC=CC=C2 Chemical compound C(C)C=1N(N=C2C1N=C(N(C2=O)C)C2=C(C=CC(=C2)S(=O)(=O)N2CCN(CC2)C)OCCC)C2=NC=CC=C2 IDBOMKWDSUDPHG-UHFFFAOYSA-N 0.000 description 1
- LTSIUXSVSKDYSR-UHFFFAOYSA-N C(C)C=1N(N=C2C1N=C(N(C2=O)C)C2=C(C=CC(=C2)S(=O)(=O)N2CCN(CC2)C)OCCOC)C2=NC=CC=C2 Chemical compound C(C)C=1N(N=C2C1N=C(N(C2=O)C)C2=C(C=CC(=C2)S(=O)(=O)N2CCN(CC2)C)OCCOC)C2=NC=CC=C2 LTSIUXSVSKDYSR-UHFFFAOYSA-N 0.000 description 1
- VSPHLCRIUIWJAN-UHFFFAOYSA-N C(C)C=1N(N=C2C1N=C(N(C2=O)C)C2=C(C=CC(=C2)S(=O)(=O)N2CCN(CC2)CC)OCCC)C=2N=NC=CC2 Chemical compound C(C)C=1N(N=C2C1N=C(N(C2=O)C)C2=C(C=CC(=C2)S(=O)(=O)N2CCN(CC2)CC)OCCC)C=2N=NC=CC2 VSPHLCRIUIWJAN-UHFFFAOYSA-N 0.000 description 1
- DZSYSZXYFIEUGT-UHFFFAOYSA-N C(C)C=1N(N=C2C1N=C(N(C2=O)C)C2=C(C=CC(=C2)S(=O)(=O)N2CCN(CC2)CC)OCCOC)C2=NC=CC=C2 Chemical compound C(C)C=1N(N=C2C1N=C(N(C2=O)C)C2=C(C=CC(=C2)S(=O)(=O)N2CCN(CC2)CC)OCCOC)C2=NC=CC=C2 DZSYSZXYFIEUGT-UHFFFAOYSA-N 0.000 description 1
- UZLHGQKSEPHNBW-UHFFFAOYSA-N C(C)C=1N(N=C2C1N=C(N(C2=O)C)C2=C(C=CC(=C2)S(=O)(=O)N2CCNCC2)OCCC)C2=NC=CC=C2 Chemical compound C(C)C=1N(N=C2C1N=C(N(C2=O)C)C2=C(C=CC(=C2)S(=O)(=O)N2CCNCC2)OCCC)C2=NC=CC=C2 UZLHGQKSEPHNBW-UHFFFAOYSA-N 0.000 description 1
- LBKXLTBXODYMMD-UHFFFAOYSA-N C(C)C=1N(N=C2C1N=C(N(C2=O)C)C2=C(C=CC=C2)OCCC)C2=NC=CC=C2 Chemical compound C(C)C=1N(N=C2C1N=C(N(C2=O)C)C2=C(C=CC=C2)OCCC)C2=NC=CC=C2 LBKXLTBXODYMMD-UHFFFAOYSA-N 0.000 description 1
- GDLZKCOSUCFOAY-UHFFFAOYSA-N C(C)C=1N(N=C2C1N=C(N(C2=O)C)C2=C(C=CC=C2)OCCC)C2=NC=CN=C2 Chemical compound C(C)C=1N(N=C2C1N=C(N(C2=O)C)C2=C(C=CC=C2)OCCC)C2=NC=CN=C2 GDLZKCOSUCFOAY-UHFFFAOYSA-N 0.000 description 1
- ZOQOJFBBVWMFNG-UHFFFAOYSA-N C(C)C=1N(N=C2C1N=C(N(C2=O)C)C2=C(C=CC=C2)OCCC)C=2N=NC=CC2 Chemical compound C(C)C=1N(N=C2C1N=C(N(C2=O)C)C2=C(C=CC=C2)OCCC)C=2N=NC=CC2 ZOQOJFBBVWMFNG-UHFFFAOYSA-N 0.000 description 1
- OELBXOWFRYJMSQ-UHFFFAOYSA-N C(C)C=1N(N=C2C1N=C(N(C2=O)C)C2=C(C=CC=C2)OCCOC)C2=NC=CC=C2 Chemical compound C(C)C=1N(N=C2C1N=C(N(C2=O)C)C2=C(C=CC=C2)OCCOC)C2=NC=CC=C2 OELBXOWFRYJMSQ-UHFFFAOYSA-N 0.000 description 1
- QLTYFKHSVWNYNT-UHFFFAOYSA-N C(C)N1CCN(CC1)S(=O)(=O)C=1C=CC(=C(C1)C=1N(C(C2=C(N1)C(=NN2C2=NC=CC=C2OC)CCC)=O)C)OCCC Chemical compound C(C)N1CCN(CC1)S(=O)(=O)C=1C=CC(=C(C1)C=1N(C(C2=C(N1)C(=NN2C2=NC=CC=C2OC)CCC)=O)C)OCCC QLTYFKHSVWNYNT-UHFFFAOYSA-N 0.000 description 1
- VMXQAFCHTOIVCZ-UHFFFAOYSA-N C(C)N1CCN(CC1)S(=O)(=O)C=1C=CC(=C(C1)C=1N(C(C2=C(N1)C(=NN2C2=NC=NN2C)CCC)=O)C)OCCC Chemical compound C(C)N1CCN(CC1)S(=O)(=O)C=1C=CC(=C(C1)C=1N(C(C2=C(N1)C(=NN2C2=NC=NN2C)CCC)=O)C)OCCC VMXQAFCHTOIVCZ-UHFFFAOYSA-N 0.000 description 1
- QUKGYIRPJBTYQP-UHFFFAOYSA-N C(C)N1CCN(CC1)S(=O)(=O)C=1C=CC(=C(C1)C=1N(C(C2=C(N1)C(=NN2C2=NC=NN2CCOC)CCC)=O)C)OCCC Chemical compound C(C)N1CCN(CC1)S(=O)(=O)C=1C=CC(=C(C1)C=1N(C(C2=C(N1)C(=NN2C2=NC=NN2CCOC)CCC)=O)C)OCCC QUKGYIRPJBTYQP-UHFFFAOYSA-N 0.000 description 1
- YSOPSYBAUIHLOK-UHFFFAOYSA-N C(C)N1CCN(CC1)S(=O)(=O)C=1C=CC(=C(C1)C=1N(C(C2=C(N1)C(=NN2C=2N(C=CN2)C)CCC)=O)C)OCCC Chemical compound C(C)N1CCN(CC1)S(=O)(=O)C=1C=CC(=C(C1)C=1N(C(C2=C(N1)C(=NN2C=2N(C=CN2)C)CCC)=O)C)OCCC YSOPSYBAUIHLOK-UHFFFAOYSA-N 0.000 description 1
- HNWSRDATXYHLPD-UHFFFAOYSA-N C(C)N1CCN(CC1)S(=O)(=O)C=1C=CC(=C(C1)C=1N(C(C=2C(N1)=C(N(N2)C2=CN=NC=C2)CCC)=O)C)OCCC Chemical compound C(C)N1CCN(CC1)S(=O)(=O)C=1C=CC(=C(C1)C=1N(C(C=2C(N1)=C(N(N2)C2=CN=NC=C2)CCC)=O)C)OCCC HNWSRDATXYHLPD-UHFFFAOYSA-N 0.000 description 1
- WUBPDOBFTSGFKL-UHFFFAOYSA-N C(C)N1CCN(CC1)S(=O)(=O)C=1C=CC(=C(C1)C=1N(C(C=2C(N1)=C(N(N2)C2=NC=CC=C2OC)CCC)=O)C)OCCC Chemical compound C(C)N1CCN(CC1)S(=O)(=O)C=1C=CC(=C(C1)C=1N(C(C=2C(N1)=C(N(N2)C2=NC=CC=C2OC)CCC)=O)C)OCCC WUBPDOBFTSGFKL-UHFFFAOYSA-N 0.000 description 1
- OXDOBIWISZSZOR-UHFFFAOYSA-N C(C)N1CCN(CC1)S(=O)(=O)C=1C=CC(=C(C1)C=1N(C(C=2C(N1)=C(N(N2)C2=NC=CN=C2)CCC)=O)C)OCCC Chemical compound C(C)N1CCN(CC1)S(=O)(=O)C=1C=CC(=C(C1)C=1N(C(C=2C(N1)=C(N(N2)C2=NC=CN=C2)CCC)=O)C)OCCC OXDOBIWISZSZOR-UHFFFAOYSA-N 0.000 description 1
- NEFKPGZMJUGTAW-UHFFFAOYSA-N C(C)N1CCN(CC1)S(=O)(=O)C=1C=CC(=C(C1)C=1N(C(C=2C(N1)=C(N(N2)C2=NC=NC=C2)CCC)=O)C)OCCC Chemical compound C(C)N1CCN(CC1)S(=O)(=O)C=1C=CC(=C(C1)C=1N(C(C=2C(N1)=C(N(N2)C2=NC=NC=C2)CCC)=O)C)OCCC NEFKPGZMJUGTAW-UHFFFAOYSA-N 0.000 description 1
- OYLCHGVDIPFTGV-UHFFFAOYSA-N C(C)N1CCN(CC1)S(=O)(=O)C=1C=CC(=C(C1)C=1N(C(C=2C(N1)=C(N(N2)C2=NC=NN2C)CCC)=O)C)OCCC Chemical compound C(C)N1CCN(CC1)S(=O)(=O)C=1C=CC(=C(C1)C=1N(C(C=2C(N1)=C(N(N2)C2=NC=NN2C)CCC)=O)C)OCCC OYLCHGVDIPFTGV-UHFFFAOYSA-N 0.000 description 1
- AYCNIQWTRRGXTG-UHFFFAOYSA-N C(C)N1CCN(CC1)S(=O)(=O)C=1C=CC(=C(C1)C=1N(C(C=2C(N1)=C(N(N2)C2=NC=NN2CCOC)CCC)=O)C)OCCC Chemical compound C(C)N1CCN(CC1)S(=O)(=O)C=1C=CC(=C(C1)C=1N(C(C=2C(N1)=C(N(N2)C2=NC=NN2CCOC)CCC)=O)C)OCCC AYCNIQWTRRGXTG-UHFFFAOYSA-N 0.000 description 1
- AUNFLLFKVYQRCU-UHFFFAOYSA-N C(C)N1CCN(CC1)S(=O)(=O)C=1C=CC(=C(C1)C=1N(C(C=2C(N1)=C(N(N2)C2=NOC(=N2)C)CCC)=O)C)OCCC Chemical compound C(C)N1CCN(CC1)S(=O)(=O)C=1C=CC(=C(C1)C=1N(C(C=2C(N1)=C(N(N2)C2=NOC(=N2)C)CCC)=O)C)OCCC AUNFLLFKVYQRCU-UHFFFAOYSA-N 0.000 description 1
- HMONRGQDRWBKNA-UHFFFAOYSA-N C(C)N1CCN(CC1)S(=O)(=O)C=1C=CC(=C(C1)C=1N(C(C=2C(N1)=C(N(N2)C2=[N+](C=CC=C2)[O-])CCC)=O)C)OCCC Chemical compound C(C)N1CCN(CC1)S(=O)(=O)C=1C=CC(=C(C1)C=1N(C(C=2C(N1)=C(N(N2)C2=[N+](C=CC=C2)[O-])CCC)=O)C)OCCC HMONRGQDRWBKNA-UHFFFAOYSA-N 0.000 description 1
- PLCNNNBMJRRJPK-UHFFFAOYSA-N C(C)N1CCN(CC1)S(=O)(=O)C=1C=CC(=C(C1)C=1N(C(C=2C(N1)=C(N(N2)C=2C=NC=CC2)CCC)=O)C)OCCC Chemical compound C(C)N1CCN(CC1)S(=O)(=O)C=1C=CC(=C(C1)C=1N(C(C=2C(N1)=C(N(N2)C=2C=NC=CC2)CCC)=O)C)OCCC PLCNNNBMJRRJPK-UHFFFAOYSA-N 0.000 description 1
- NXPQHHVUENNQAC-UHFFFAOYSA-N C(C)N1CCN(CC1)S(=O)(=O)C=1C=CC(=C(C1)C=1N(C(C=2C(N1)=C(N(N2)C=2C=NC=NC2)CCC)=O)C)OCCC Chemical compound C(C)N1CCN(CC1)S(=O)(=O)C=1C=CC(=C(C1)C=1N(C(C=2C(N1)=C(N(N2)C=2C=NC=NC2)CCC)=O)C)OCCC NXPQHHVUENNQAC-UHFFFAOYSA-N 0.000 description 1
- UYQZVZJDHMGIDW-UHFFFAOYSA-N C(C)N1CCN(CC1)S(=O)(=O)C=1C=CC(=C(C1)C=1N(C(C=2C(N1)=C(N(N2)C=2N(C=CN2)C)CCC)=O)C)OCCC Chemical compound C(C)N1CCN(CC1)S(=O)(=O)C=1C=CC(=C(C1)C=1N(C(C=2C(N1)=C(N(N2)C=2N(C=CN2)C)CCC)=O)C)OCCC UYQZVZJDHMGIDW-UHFFFAOYSA-N 0.000 description 1
- HLPGVOBCOMEVTL-UHFFFAOYSA-N C(C)N1CCN(CC1)S(=O)(=O)C=1C=CC(=C(C1)C=1N(C(C=2C(N1)=C(N(N2)C=2N=NC=CC2)CCC)=O)C)OCCC Chemical compound C(C)N1CCN(CC1)S(=O)(=O)C=1C=CC(=C(C1)C=1N(C(C=2C(N1)=C(N(N2)C=2N=NC=CC2)CCC)=O)C)OCCC HLPGVOBCOMEVTL-UHFFFAOYSA-N 0.000 description 1
- ROFFEMBBRIFSOP-UHFFFAOYSA-N C(C)OC1=C(C=C(C=C1)S(=O)(=O)N1CCN(CC1)C)C=1N(C(C2=C(N1)C(=NN2C=2C(=NOC2C)C)C)=O)C Chemical compound C(C)OC1=C(C=C(C=C1)S(=O)(=O)N1CCN(CC1)C)C=1N(C(C2=C(N1)C(=NN2C=2C(=NOC2C)C)C)=O)C ROFFEMBBRIFSOP-UHFFFAOYSA-N 0.000 description 1
- FBKKFCNJDBFQPT-UHFFFAOYSA-N C(C)OC1=C(C=C(C=C1)S(=O)(=O)N1CCN(CC1)C)C=1N(C(C=2C(N1)=C(N(N2)C2=NC=CC=C2)C)=O)C Chemical compound C(C)OC1=C(C=C(C=C1)S(=O)(=O)N1CCN(CC1)C)C=1N(C(C=2C(N1)=C(N(N2)C2=NC=CC=C2)C)=O)C FBKKFCNJDBFQPT-UHFFFAOYSA-N 0.000 description 1
- LTPLAHDRUWGKDF-UHFFFAOYSA-N C(C)OC1=C(C=C(C=C1)S(=O)(=O)N1CCN(CC1)C)C=1N(C(C=2C(N1)=C(N(N2)C2=NC=CC=C2)CCC)=O)C Chemical compound C(C)OC1=C(C=C(C=C1)S(=O)(=O)N1CCN(CC1)C)C=1N(C(C=2C(N1)=C(N(N2)C2=NC=CC=C2)CCC)=O)C LTPLAHDRUWGKDF-UHFFFAOYSA-N 0.000 description 1
- MXJFUGMWWQFHEO-UHFFFAOYSA-N C(C)OC1=C(C=C(C=C1)S(=O)(=O)N1CCN(CC1)C)C=1N(C(C=2C(N1)=C(N(N2)C=2N=C(SC2)C)C)=O)C Chemical compound C(C)OC1=C(C=C(C=C1)S(=O)(=O)N1CCN(CC1)C)C=1N(C(C=2C(N1)=C(N(N2)C=2N=C(SC2)C)C)=O)C MXJFUGMWWQFHEO-UHFFFAOYSA-N 0.000 description 1
- XLIHPFRREZOOAY-UHFFFAOYSA-N C(C)OC1=C(C=C(C=C1)S(=O)(=O)N1CCN(CC1)CCO)C=1N(C(C=2C(N1)=C(N(N2)C2=NC=CC=C2)C)=O)C Chemical compound C(C)OC1=C(C=C(C=C1)S(=O)(=O)N1CCN(CC1)CCO)C=1N(C(C=2C(N1)=C(N(N2)C2=NC=CC=C2)C)=O)C XLIHPFRREZOOAY-UHFFFAOYSA-N 0.000 description 1
- HJEHNSJRMKWSPO-UHFFFAOYSA-N C(C)OC1=C(C=C(C=C1)S(=O)(=O)N1CCN(CC1)CCO)C=1N(C(C=2C(N1)=C(N(N2)C2=NOC(=N2)C)CCC)=O)C Chemical compound C(C)OC1=C(C=C(C=C1)S(=O)(=O)N1CCN(CC1)CCO)C=1N(C(C=2C(N1)=C(N(N2)C2=NOC(=N2)C)CCC)=O)C HJEHNSJRMKWSPO-UHFFFAOYSA-N 0.000 description 1
- FHYOUVYGIQCUPK-UHFFFAOYSA-N C(C)OC1=C(C=CC=C1)C=1N(C(C=2C(N1)=C(N(N2)C2=NC=CC=C2)CCC)=O)C Chemical compound C(C)OC1=C(C=CC=C1)C=1N(C(C=2C(N1)=C(N(N2)C2=NC=CC=C2)CCC)=O)C FHYOUVYGIQCUPK-UHFFFAOYSA-N 0.000 description 1
- JWXMMFPLFFGZJS-UHFFFAOYSA-N C(C)OC1=C(C=CC=C1)C=1N(C(C=2C(N1)=C(N(N2)C2=NOC(=N2)C)CCC)=O)C Chemical compound C(C)OC1=C(C=CC=C1)C=1N(C(C=2C(N1)=C(N(N2)C2=NOC(=N2)C)CCC)=O)C JWXMMFPLFFGZJS-UHFFFAOYSA-N 0.000 description 1
- ZHXDITICHCZMKJ-UHFFFAOYSA-N C(CC(O)(C(=O)O)CC(=O)O)(=O)O.C(C)C=1N(N=C2C1N=C(N(C2=O)C)C2=C(C=CC(=C2)S(=O)(=O)N2CCN(CC2)CC)OCCC)C2=NC=CC=C2 Chemical compound C(CC(O)(C(=O)O)CC(=O)O)(=O)O.C(C)C=1N(N=C2C1N=C(N(C2=O)C)C2=C(C=CC(=C2)S(=O)(=O)N2CCN(CC2)CC)OCCC)C2=NC=CC=C2 ZHXDITICHCZMKJ-UHFFFAOYSA-N 0.000 description 1
- ZSSHSIHYKBQWBM-UHFFFAOYSA-N C(CC)OC1=C(C=CC=C1)C=1N(C(C2=C(N1)C(=NN2C2=NC=CC=C2)CCC)=O)C Chemical compound C(CC)OC1=C(C=CC=C1)C=1N(C(C2=C(N1)C(=NN2C2=NC=CC=C2)CCC)=O)C ZSSHSIHYKBQWBM-UHFFFAOYSA-N 0.000 description 1
- MVZOUEAKEGYIMX-UHFFFAOYSA-N C(CC)OC1=C(C=CC=C1)C=1N(C(C=2C(N1)=C(N(N2)C2=CN=NC=C2)CCC)=O)C Chemical compound C(CC)OC1=C(C=CC=C1)C=1N(C(C=2C(N1)=C(N(N2)C2=CN=NC=C2)CCC)=O)C MVZOUEAKEGYIMX-UHFFFAOYSA-N 0.000 description 1
- SVTPOLYXLPRGPO-UHFFFAOYSA-N C(CC)OC1=C(C=CC=C1)C=1N(C(C=2C(N1)=C(N(N2)C2=NC=NC=C2)CCC)=O)C Chemical compound C(CC)OC1=C(C=CC=C1)C=1N(C(C=2C(N1)=C(N(N2)C2=NC=NC=C2)CCC)=O)C SVTPOLYXLPRGPO-UHFFFAOYSA-N 0.000 description 1
- VYKDJUUUKJYKPT-UHFFFAOYSA-N C(CC)OC1=C(C=CC=C1)C=1N(C(C=2C(N1)=C(N(N2)C=2C=NC=NC2)CCC)=O)C Chemical compound C(CC)OC1=C(C=CC=C1)C=1N(C(C=2C(N1)=C(N(N2)C=2C=NC=NC2)CCC)=O)C VYKDJUUUKJYKPT-UHFFFAOYSA-N 0.000 description 1
- FKKWCWMQBYIODU-UHFFFAOYSA-N C(CC)OC1=C(C=CC=C1)C=1N(C(C=2C(N1)=C(N(N2)C=2N=NC=CC2)CCC)=O)C Chemical compound C(CC)OC1=C(C=CC=C1)C=1N(C(C=2C(N1)=C(N(N2)C=2N=NC=CC2)CCC)=O)C FKKWCWMQBYIODU-UHFFFAOYSA-N 0.000 description 1
- UMERQFGBBCRIQY-UHFFFAOYSA-N C(N)(=O)CN1CCN(CC1)S(=O)(=O)C=1C=CC(=C(C1)C=1N(C(C2=C(N1)C(=NN2C=2N(C=CN2)C)CCC)=O)C)OCCC Chemical compound C(N)(=O)CN1CCN(CC1)S(=O)(=O)C=1C=CC(=C(C1)C=1N(C(C2=C(N1)C(=NN2C=2N(C=CN2)C)CCC)=O)C)OCCC UMERQFGBBCRIQY-UHFFFAOYSA-N 0.000 description 1
- ZXJNWXKSLMGKCG-UHFFFAOYSA-N C(N)(=O)CN1CCN(CC1)S(=O)(=O)C=1C=CC(=C(C1)C=1N(C(C=2C(N1)=C(N(N2)C2=NC=CC=C2)CCC)=O)C)OCCC Chemical compound C(N)(=O)CN1CCN(CC1)S(=O)(=O)C=1C=CC(=C(C1)C=1N(C(C=2C(N1)=C(N(N2)C2=NC=CC=C2)CCC)=O)C)OCCC ZXJNWXKSLMGKCG-UHFFFAOYSA-N 0.000 description 1
- KOYWFICMKPFITL-UHFFFAOYSA-N CC1=NC(=NO1)N1N=C2C(N=C(N(C2=O)C)C2=C(C=CC(=C2)S(=O)(=O)N2CCN(CC2)C)OCCC)=C1CCC Chemical compound CC1=NC(=NO1)N1N=C2C(N=C(N(C2=O)C)C2=C(C=CC(=C2)S(=O)(=O)N2CCN(CC2)C)OCCC)=C1CCC KOYWFICMKPFITL-UHFFFAOYSA-N 0.000 description 1
- SJYKGLKCJGTCCI-UHFFFAOYSA-N CC1=NC(=NO1)N1N=C2C(N=C(N(C2=O)C)C2=C(C=CC=C2)OCCC)=C1CCC Chemical compound CC1=NC(=NO1)N1N=C2C(N=C(N(C2=O)C)C2=C(C=CC=C2)OCCC)=C1CCC SJYKGLKCJGTCCI-UHFFFAOYSA-N 0.000 description 1
- USFAKPNRJPECNC-UHFFFAOYSA-N CC1=NOC(=C1N1N=C2C(N=C(N(C2=O)C)C2=C(C=CC(=C2)S(=O)(=O)N2CCN(CC2)C)OCCC)=C1CCC)C Chemical compound CC1=NOC(=C1N1N=C2C(N=C(N(C2=O)C)C2=C(C=CC(=C2)S(=O)(=O)N2CCN(CC2)C)OCCC)=C1CCC)C USFAKPNRJPECNC-UHFFFAOYSA-N 0.000 description 1
- JIAOQNFANAYNBN-UHFFFAOYSA-N CC=1SC=C(N1)N1N=C2C(N=C(N(C2=O)C)C2=C(C=CC=C2)OCCC)=C1CCC Chemical compound CC=1SC=C(N1)N1N=C2C(N=C(N(C2=O)C)C2=C(C=CC=C2)OCCC)=C1CCC JIAOQNFANAYNBN-UHFFFAOYSA-N 0.000 description 1
- QIRHTRZFGORUOD-UHFFFAOYSA-N CCCC1=C2C(=NN1C3=NOC(=N3)C)C(=O)N(C(=N2)C4=C(C=CC(=C4)S(=O)(=O)N5CCN(CC5)C)OCC)C Chemical compound CCCC1=C2C(=NN1C3=NOC(=N3)C)C(=O)N(C(=N2)C4=C(C=CC(=C4)S(=O)(=O)N5CCN(CC5)C)OCC)C QIRHTRZFGORUOD-UHFFFAOYSA-N 0.000 description 1
- UYLPXLRBGLRTNK-UHFFFAOYSA-N CCCOC1=C(C=C(C=C1)S(=O)(=O)N2CCN(CC2)CC)C3=NC4=C(C(=O)N3C)N(N=C4CC)C5=CC=CC=N5 Chemical compound CCCOC1=C(C=C(C=C1)S(=O)(=O)N2CCN(CC2)CC)C3=NC4=C(C(=O)N3C)N(N=C4CC)C5=CC=CC=N5 UYLPXLRBGLRTNK-UHFFFAOYSA-N 0.000 description 1
- DPDPLTLRGGKAMV-UHFFFAOYSA-N CCCOC1=C(C=C(C=C1)S(=O)(=O)N2CCN(CC2)CCO)C3=NC4=C(N(N=C4C(=O)N3C)C5=CC=CC=N5)CC Chemical compound CCCOC1=C(C=C(C=C1)S(=O)(=O)N2CCN(CC2)CCO)C3=NC4=C(N(N=C4C(=O)N3C)C5=CC=CC=N5)CC DPDPLTLRGGKAMV-UHFFFAOYSA-N 0.000 description 1
- JHMSBKZJUOXPGR-UHFFFAOYSA-N CN1C(=NC=C1)N1N=C(C=2N=C(N(C(C21)=O)C)C2=C(C=CC(=C2)S(=O)(=O)N2CCN(CC2)C)OCCC)CCC Chemical compound CN1C(=NC=C1)N1N=C(C=2N=C(N(C(C21)=O)C)C2=C(C=CC(=C2)S(=O)(=O)N2CCN(CC2)C)OCCC)CCC JHMSBKZJUOXPGR-UHFFFAOYSA-N 0.000 description 1
- VCHMDYPVOYEKFF-UHFFFAOYSA-N CN1C(=NC=C1)N1N=C2C(N=C(N(C2=O)C)C2=C(C=CC(=C2)S(=O)(=O)N2CCN(CC2)C)OCCC)=C1CCC Chemical compound CN1C(=NC=C1)N1N=C2C(N=C(N(C2=O)C)C2=C(C=CC(=C2)S(=O)(=O)N2CCN(CC2)C)OCCC)=C1CCC VCHMDYPVOYEKFF-UHFFFAOYSA-N 0.000 description 1
- LREMCYZMNMMHSZ-UHFFFAOYSA-N CN1C(=NC=C1)N1N=C2C(N=C(N(C2=O)C)C2=C(C=CC=C2)OCCC)=C1CCC Chemical compound CN1C(=NC=C1)N1N=C2C(N=C(N(C2=O)C)C2=C(C=CC=C2)OCCC)=C1CCC LREMCYZMNMMHSZ-UHFFFAOYSA-N 0.000 description 1
- HLRVRTUKJFQDJK-UHFFFAOYSA-N CN1C(=NN=C1)N1N=C(C=2N=C(N(C(C21)=O)C)C2=C(C=CC=C2)OCCC)CCC Chemical compound CN1C(=NN=C1)N1N=C(C=2N=C(N(C(C21)=O)C)C2=C(C=CC=C2)OCCC)CCC HLRVRTUKJFQDJK-UHFFFAOYSA-N 0.000 description 1
- UWZXHINFZROABQ-UHFFFAOYSA-N CN1CCN(CC1)S(=O)(=O)C=1C=CC(=C(C1)C=1N(C(C2=C(N1)C(=NN2C2=NC=CC=C2)CCC)=O)C)OCCC Chemical compound CN1CCN(CC1)S(=O)(=O)C=1C=CC(=C(C1)C=1N(C(C2=C(N1)C(=NN2C2=NC=CC=C2)CCC)=O)C)OCCC UWZXHINFZROABQ-UHFFFAOYSA-N 0.000 description 1
- MIZSVXZUDSLMFK-UHFFFAOYSA-N CN1CCN(CC1)S(=O)(=O)C=1C=CC(=C(C1)C=1N(C(C2=C(N1)C(=NN2C2=NOC=N2)CCC)=O)C)OCCC Chemical compound CN1CCN(CC1)S(=O)(=O)C=1C=CC(=C(C1)C=1N(C(C2=C(N1)C(=NN2C2=NOC=N2)CCC)=O)C)OCCC MIZSVXZUDSLMFK-UHFFFAOYSA-N 0.000 description 1
- XZBAAWXJCTZBGZ-UHFFFAOYSA-N CN1CCN(CC1)S(=O)(=O)C=1C=CC(=C(C1)C=1N(C(C2=C(N1)C(=NN2C=2N=C(SC2)C)CCC)=O)C)OCCC Chemical compound CN1CCN(CC1)S(=O)(=O)C=1C=CC(=C(C1)C=1N(C(C2=C(N1)C(=NN2C=2N=C(SC2)C)CCC)=O)C)OCCC XZBAAWXJCTZBGZ-UHFFFAOYSA-N 0.000 description 1
- DAEYUYJEWOUILH-UHFFFAOYSA-N CN1CCN(CC1)S(=O)(=O)C=1C=CC(=C(C1)C=1N(C(C=2C(N1)=C(N(N2)C2=NC=CC=C2)CCC)=O)C)OCCC Chemical compound CN1CCN(CC1)S(=O)(=O)C=1C=CC(=C(C1)C=1N(C(C=2C(N1)=C(N(N2)C2=NC=CC=C2)CCC)=O)C)OCCC DAEYUYJEWOUILH-UHFFFAOYSA-N 0.000 description 1
- ILDWKRJTGQBLCB-UHFFFAOYSA-N CN1CCN(CC1)S(=O)(=O)C=1C=CC(=C(C1)C=1N(C(C=2C(N1)=C(N(N2)C2=[N+](C=CC=C2)[O-])CCC)=O)C)OCCC Chemical compound CN1CCN(CC1)S(=O)(=O)C=1C=CC(=C(C1)C=1N(C(C=2C(N1)=C(N(N2)C2=[N+](C=CC=C2)[O-])CCC)=O)C)OCCC ILDWKRJTGQBLCB-UHFFFAOYSA-N 0.000 description 1
- UWEOEUZLNIKSQC-UHFFFAOYSA-N CN1CCN(CC1)S(=O)(=O)C=1C=CC(=C(C1)C=1N(C(C=2C(N1)=C(N(N2)C=2N=C(SC2)C)CCC)=O)C)OCCC Chemical compound CN1CCN(CC1)S(=O)(=O)C=1C=CC(=C(C1)C=1N(C(C=2C(N1)=C(N(N2)C=2N=C(SC2)C)CCC)=O)C)OCCC UWEOEUZLNIKSQC-UHFFFAOYSA-N 0.000 description 1
- PHSQGMBVMOKHCW-UHFFFAOYSA-N CN1N=CN=C1N1N=C2C(N=C(N(C2=O)C)C2=C(C=CC=C2)OCCC)=C1CCC Chemical compound CN1N=CN=C1N1N=C2C(N=C(N(C2=O)C)C2=C(C=CC=C2)OCCC)=C1CCC PHSQGMBVMOKHCW-UHFFFAOYSA-N 0.000 description 1
- ALBMDOPECIVMJT-UHFFFAOYSA-N COC1=C(C=C(C=C1)S(=O)(=O)N1CCN(CC1)C)C=1N(C(C2=C(N1)C(=NN2C2=NC=CC=C2)CCC)=O)C Chemical compound COC1=C(C=C(C=C1)S(=O)(=O)N1CCN(CC1)C)C=1N(C(C2=C(N1)C(=NN2C2=NC=CC=C2)CCC)=O)C ALBMDOPECIVMJT-UHFFFAOYSA-N 0.000 description 1
- QERYQGPFPGXOEX-UHFFFAOYSA-N COC1=C(C=CC=C1)C=1N(C(C=2C(N1)=C(N(N2)C2=NC=CC=C2)CCC)=O)C Chemical compound COC1=C(C=CC=C1)C=1N(C(C=2C(N1)=C(N(N2)C2=NC=CC=C2)CCC)=O)C QERYQGPFPGXOEX-UHFFFAOYSA-N 0.000 description 1
- UXSIDBMMOLCTLY-UHFFFAOYSA-N COC=1C(=NC=CC1)N1N=C(C=2N=C(N(C(C21)=O)C)C2=C(C=CC=C2)OCCC)CCC Chemical compound COC=1C(=NC=CC1)N1N=C(C=2N=C(N(C(C21)=O)C)C2=C(C=CC=C2)OCCC)CCC UXSIDBMMOLCTLY-UHFFFAOYSA-N 0.000 description 1
- ZJHWSFSOFAKMFB-UHFFFAOYSA-N COC=1C(=NC=CC1)N1N=C2C(N=C(N(C2=O)C)C2=C(C=CC(=C2)S(=O)(=O)N2CCN(CC2)C)OCCC)=C1CCC Chemical compound COC=1C(=NC=CC1)N1N=C2C(N=C(N(C2=O)C)C2=C(C=CC(=C2)S(=O)(=O)N2CCN(CC2)C)OCCC)=C1CCC ZJHWSFSOFAKMFB-UHFFFAOYSA-N 0.000 description 1
- OCGIIBZVIPRZNY-UHFFFAOYSA-N COCCN1N=CN=C1N1N=C(C=2N=C(N(C(C21)=O)C)C2=C(C=CC(=C2)S(=O)(=O)N2CCN(CC2)C)OCCC)CCC Chemical compound COCCN1N=CN=C1N1N=C(C=2N=C(N(C(C21)=O)C)C2=C(C=CC(=C2)S(=O)(=O)N2CCN(CC2)C)OCCC)CCC OCGIIBZVIPRZNY-UHFFFAOYSA-N 0.000 description 1
- VWTGOUDIMRZAQP-UHFFFAOYSA-N COCCN1N=CN=C1N1N=C(C=2N=C(N(C(C21)=O)C)C2=C(C=CC=C2)OCCC)CCC Chemical compound COCCN1N=CN=C1N1N=C(C=2N=C(N(C(C21)=O)C)C2=C(C=CC=C2)OCCC)CCC VWTGOUDIMRZAQP-UHFFFAOYSA-N 0.000 description 1
- JJOAAAXSFYOGHQ-UHFFFAOYSA-N COCCN1N=CN=C1N1N=C2C(N=C(N(C2=O)C)C2=C(C=CC=C2)OCCC)=C1CCC Chemical compound COCCN1N=CN=C1N1N=C2C(N=C(N(C2=O)C)C2=C(C=CC=C2)OCCC)=C1CCC JJOAAAXSFYOGHQ-UHFFFAOYSA-N 0.000 description 1
- 101100167280 Caenorhabditis elegans cin-4 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- CDDBRHRDWOCBFI-UHFFFAOYSA-N FC(C(=O)O)(F)F.N1(CCNCC1)S(=O)(=O)C=1C=CC(=C(C1)C=1N(C(C=2C(N1)=C(N(N2)C2=NC=CC=C2)CCC)=O)C)OCCC Chemical compound FC(C(=O)O)(F)F.N1(CCNCC1)S(=O)(=O)C=1C=CC(=C(C1)C=1N(C(C=2C(N1)=C(N(N2)C2=NC=CC=C2)CCC)=O)C)OCCC CDDBRHRDWOCBFI-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- 230000006181 N-acylation Effects 0.000 description 1
- 238000007126 N-alkylation reaction Methods 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- FAYDTBZZWXACJE-UHFFFAOYSA-N OCCN1CCN(CC1)S(=O)(=O)C=1C=CC(=C(C1)C=1N(C(C2=C(N1)C(=NN2C2=NC=CC=C2)CCC)=O)C)OCCC Chemical compound OCCN1CCN(CC1)S(=O)(=O)C=1C=CC(=C(C1)C=1N(C(C2=C(N1)C(=NN2C2=NC=CC=C2)CCC)=O)C)OCCC FAYDTBZZWXACJE-UHFFFAOYSA-N 0.000 description 1
- OJCXXUYAJXJQHB-UHFFFAOYSA-N OCCN1CCN(CC1)S(=O)(=O)C=1C=CC(=C(C1)C=1N(C(C2=C(N1)C(=NN2C2=NC=NN2C)CCC)=O)C)OCCC Chemical compound OCCN1CCN(CC1)S(=O)(=O)C=1C=CC(=C(C1)C=1N(C(C2=C(N1)C(=NN2C2=NC=NN2C)CCC)=O)C)OCCC OJCXXUYAJXJQHB-UHFFFAOYSA-N 0.000 description 1
- DUFJVBNCZNSCHT-UHFFFAOYSA-N OCCN1CCN(CC1)S(=O)(=O)C=1C=CC(=C(C1)C=1N(C(C2=C(N1)C(=NN2C2=NN=CN2C)CCC)=O)C)OCCC Chemical compound OCCN1CCN(CC1)S(=O)(=O)C=1C=CC(=C(C1)C=1N(C(C2=C(N1)C(=NN2C2=NN=CN2C)CCC)=O)C)OCCC DUFJVBNCZNSCHT-UHFFFAOYSA-N 0.000 description 1
- BDRKFVMARPGNIY-UHFFFAOYSA-N OCCN1CCN(CC1)S(=O)(=O)C=1C=CC(=C(C1)C=1N(C(C=2C(N1)=C(N(N2)C2=NC=CC=C2)CCC)=O)C)OCCC Chemical compound OCCN1CCN(CC1)S(=O)(=O)C=1C=CC(=C(C1)C=1N(C(C=2C(N1)=C(N(N2)C2=NC=CC=C2)CCC)=O)C)OCCC BDRKFVMARPGNIY-UHFFFAOYSA-N 0.000 description 1
- JODVLTKTCZTRKM-UHFFFAOYSA-N OCCN1CCN(CC1)S(=O)(=O)C=1C=CC(=C(C1)C=1N(C(C=2C(N1)=C(N(N2)C=2N(C=CN2)C)CCC)=O)C)OCCC Chemical compound OCCN1CCN(CC1)S(=O)(=O)C=1C=CC(=C(C1)C=1N(C(C=2C(N1)=C(N(N2)C=2N(C=CN2)C)CCC)=O)C)OCCC JODVLTKTCZTRKM-UHFFFAOYSA-N 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- OEYVFRVNVPKHQQ-UHFFFAOYSA-N Pyrimidin-4-yl-Methanol Chemical compound OCC1=CC=NC=N1 OEYVFRVNVPKHQQ-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- 239000009975 Urodyn Substances 0.000 description 1
- SVBRQDQGYGFFFY-UHFFFAOYSA-N [2-(2-methoxyethyl)-1,2,4-triazol-3-yl]methanol Chemical compound COCCN1N=CN=C1CO SVBRQDQGYGFFFY-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 229940121359 adenosine receptor antagonist Drugs 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 238000010936 aqueous wash Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 description 1
- 125000000043 benzamido group Chemical group [H]N([*])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- YEJBTHKLPZRNCK-UHFFFAOYSA-N benzyl 2-[7-oxo-5-(2-propoxyphenyl)-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-2-yl]acetate Chemical compound CCCOC1=CC=CC=C1C(NC(=O)C1=N2)=NC1=C(CCC)N2CC(=O)OCC1=CC=CC=C1 YEJBTHKLPZRNCK-UHFFFAOYSA-N 0.000 description 1
- OBTQVPHZGZGHKP-UHFFFAOYSA-N benzyl 2-benzyl-4-nitro-5-propylpyrazole-3-carboxylate Chemical compound C=1C=CC=CC=1COC(=O)C1=C([N+]([O-])=O)C(CCC)=NN1CC1=CC=CC=C1 OBTQVPHZGZGHKP-UHFFFAOYSA-N 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 239000012455 biphasic mixture Substances 0.000 description 1
- 230000003182 bronchodilatating effect Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- YKGMKSIHIVVYKY-UHFFFAOYSA-N dabrafenib mesylate Chemical compound CS(O)(=O)=O.S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 YKGMKSIHIVVYKY-UHFFFAOYSA-N 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- WYACBZDAHNBPPB-UHFFFAOYSA-N diethyl oxalate Chemical compound CCOC(=O)C(=O)OCC WYACBZDAHNBPPB-UHFFFAOYSA-N 0.000 description 1
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- FRYHCSODNHYDPU-UHFFFAOYSA-N ethanesulfonyl chloride Chemical compound CCS(Cl)(=O)=O FRYHCSODNHYDPU-UHFFFAOYSA-N 0.000 description 1
- WCQOBLXWLRDEQA-UHFFFAOYSA-N ethanimidamide;hydrochloride Chemical compound Cl.CC(N)=N WCQOBLXWLRDEQA-UHFFFAOYSA-N 0.000 description 1
- YFONSBZEAHNVCW-UHFFFAOYSA-N ethyl 5-ethyl-1h-pyrazole-3-carboxylate Chemical compound CCOC(=O)C=1C=C(CC)NN=1 YFONSBZEAHNVCW-UHFFFAOYSA-N 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- JBFYUZGYRGXSFL-UHFFFAOYSA-N imidazolide Chemical compound C1=C[N-]C=N1 JBFYUZGYRGXSFL-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940030980 inova Drugs 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 239000007926 intracavernous injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229910000103 lithium hydride Inorganic materials 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000003328 mesylation reaction Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- OWLJWMUARMTUHZ-UHFFFAOYSA-N methyl 2-(2-methoxyethoxy)benzoate Chemical compound COCCOC1=CC=CC=C1C(=O)OC OWLJWMUARMTUHZ-UHFFFAOYSA-N 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- LOOCNCIUGPYGJL-UHFFFAOYSA-N n-[2-[5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-propoxyphenyl]-7-oxo-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-2-yl]phenyl]methanesulfonamide Chemical compound CCCOC1=CC=C(S(=O)(=O)N2CCN(CC)CC2)C=C1C(NC(=O)C1=N2)=NC1=C(CCC)N2C1=CC=CC=C1NS(C)(=O)=O LOOCNCIUGPYGJL-UHFFFAOYSA-N 0.000 description 1
- HSZWYEMWLPKYEL-UHFFFAOYSA-N n-[2-[[5-[2-ethoxy-5-(4-methylpiperazin-1-yl)sulfonylphenyl]-7-oxo-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-1-yl]methyl]phenyl]methanesulfonamide Chemical compound N1=C(C=2C(=CC=C(C=2)S(=O)(=O)N2CCN(C)CC2)OCC)NC(=O)C2=C1C(CCC)=NN2CC1=CC=CC=C1NS(C)(=O)=O HSZWYEMWLPKYEL-UHFFFAOYSA-N 0.000 description 1
- JBPOUAAFHSLMCQ-UHFFFAOYSA-N n-[2-[[5-[5-[4-[2-[tert-butyl(dimethyl)silyl]oxyethyl]piperazin-1-yl]sulfonyl-2-propoxyphenyl]-7-oxo-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-1-yl]methyl]phenyl]methanesulfonamide Chemical compound CCCOC1=CC=C(S(=O)(=O)N2CCN(CCO[Si](C)(C)C(C)(C)C)CC2)C=C1C(NC=1C(CCC)=N2)=NC(=O)C=1N2CC1=CC=CC=C1NS(C)(=O)=O JBPOUAAFHSLMCQ-UHFFFAOYSA-N 0.000 description 1
- QZGQQCKLDOONNY-UHFFFAOYSA-N n-[4-[5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-propoxyphenyl]-7-oxo-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-2-yl]phenyl]ethanesulfonamide Chemical compound CCCOC1=CC=C(S(=O)(=O)N2CCN(CC)CC2)C=C1C(NC(=O)C1=N2)=NC1=C(CCC)N2C1=CC=C(NS(=O)(=O)CC)C=C1 QZGQQCKLDOONNY-UHFFFAOYSA-N 0.000 description 1
- YXGMNPMPWBADFX-UHFFFAOYSA-N n-[4-[5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-propoxyphenyl]-7-oxo-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-2-yl]phenyl]propane-2-sulfonamide Chemical compound CCCOC1=CC=C(S(=O)(=O)N2CCN(CC)CC2)C=C1C(NC(=O)C1=N2)=NC1=C(CCC)N2C1=CC=C(NS(=O)(=O)C(C)C)C=C1 YXGMNPMPWBADFX-UHFFFAOYSA-N 0.000 description 1
- CHWGMNUJUFPVJA-UHFFFAOYSA-N n-[4-[5-[5-(4-methylpiperazin-1-yl)sulfonyl-2-propoxyphenyl]-7-oxo-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-2-yl]phenyl]methanesulfonamide Chemical compound CCCOC1=CC=C(S(=O)(=O)N2CCN(C)CC2)C=C1C(NC(=O)C1=N2)=NC1=C(CCC)N2C1=CC=C(NS(C)(=O)=O)C=C1 CHWGMNUJUFPVJA-UHFFFAOYSA-N 0.000 description 1
- YQUKFIWOIIFAGQ-UHFFFAOYSA-N n-[4-[[5-[2-ethoxy-5-(4-methylpiperazin-1-yl)sulfonylphenyl]-7-oxo-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-1-yl]methyl]phenyl]methanesulfonamide Chemical compound N1=C(C=2C(=CC=C(C=2)S(=O)(=O)N2CCN(C)CC2)OCC)NC(=O)C2=C1C(CCC)=NN2CC1=CC=C(NS(C)(=O)=O)C=C1 YQUKFIWOIIFAGQ-UHFFFAOYSA-N 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 238000010915 one-step procedure Methods 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- KGCNHWXDPDPSBV-UHFFFAOYSA-N p-nitrobenzyl chloride Chemical compound [O-][N+](=O)C1=CC=C(CCl)C=C1 KGCNHWXDPDPSBV-UHFFFAOYSA-N 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-O phosphonium Chemical compound [PH4+] XYFCBTPGUUZFHI-UHFFFAOYSA-O 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 108091008695 photoreceptors Proteins 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 229920005990 polystyrene resin Polymers 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- DRINJBFRTLBHNF-UHFFFAOYSA-N propane-2-sulfonyl chloride Chemical compound CC(C)S(Cl)(=O)=O DRINJBFRTLBHNF-UHFFFAOYSA-N 0.000 description 1
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- WAJNANMQOPCIPO-UHFFFAOYSA-N pyrazolo[4,3-d]pyrimidin-7-one Chemical class O=C1N=CN=C2C=NN=C12 WAJNANMQOPCIPO-UHFFFAOYSA-N 0.000 description 1
- STIKETVNLGXQCS-UHFFFAOYSA-N pyridazin-3-ylmethanol Chemical compound OCC1=CC=CN=N1 STIKETVNLGXQCS-UHFFFAOYSA-N 0.000 description 1
- GXWAGVFGTPTYAO-UHFFFAOYSA-N pyridazin-4-ylmethanol Chemical compound OCC1=CC=NN=C1 GXWAGVFGTPTYAO-UHFFFAOYSA-N 0.000 description 1
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical group OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000005049 silicon tetrachloride Substances 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical group [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical class [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229940001593 sodium carbonate Drugs 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- UVMAXIWRKVCCRS-UHFFFAOYSA-N sodium;cyclohexylazanide Chemical class [Na+].[NH-]C1CCCCC1 UVMAXIWRKVCCRS-UHFFFAOYSA-N 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000001119 stannous chloride Substances 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 230000006103 sulfonylation Effects 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- HIFJUMGIHIZEPX-UHFFFAOYSA-N sulfuric acid;sulfur trioxide Chemical compound O=S(=O)=O.OS(O)(=O)=O HIFJUMGIHIZEPX-UHFFFAOYSA-N 0.000 description 1
- 229950009390 symclosene Drugs 0.000 description 1
- DKACXUFSLUYRFU-UHFFFAOYSA-N tert-butyl n-aminocarbamate Chemical compound CC(C)(C)OC(=O)NN DKACXUFSLUYRFU-UHFFFAOYSA-N 0.000 description 1
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
- 125000005951 trifluoromethanesulfonyloxy group Chemical group 0.000 description 1
- GNMJFQWRASXXMS-UHFFFAOYSA-M trimethyl(phenyl)azanium;bromide Chemical compound [Br-].C[N+](C)(C)C1=CC=CC=C1 GNMJFQWRASXXMS-UHFFFAOYSA-M 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9708406.5A GB9708406D0 (en) | 1997-04-25 | 1997-04-25 | Therapeutic agents |
GB9715380A GB9715380D0 (en) | 1997-07-22 | 1997-07-22 | Therapeutic agents |
GBGB9722954.6A GB9722954D0 (en) | 1997-10-30 | 1997-10-30 | Therapeutic agents |
PCT/EP1998/002257 WO1998049166A1 (en) | 1997-04-25 | 1998-04-10 | PYRAZOLOPYRIMIDINONES WHICH INHIBIT TYPE 5 CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE (cGMP PDE5) FOR THE TREATMENT OF SEXUAL DYSFUNCTION |
Publications (3)
Publication Number | Publication Date |
---|---|
NO995211L NO995211L (no) | 1999-10-25 |
NO995211D0 NO995211D0 (no) | 1999-10-25 |
NO314585B1 true NO314585B1 (no) | 2003-04-14 |
Family
ID=27268823
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19995211A NO314585B1 (no) | 1997-04-25 | 1999-10-25 | Pyrazolpyrimidinoner som hemmer cyklisk guanosin-3',5'- monofosfatfosfodiesterase type 5 (cGMP PDE5), for behandling av seksuell dysfunksjon |
Country Status (32)
Country | Link |
---|---|
US (2) | US6723719B1 (he) |
EP (1) | EP0977756A1 (he) |
JP (2) | JP3563078B2 (he) |
KR (2) | KR100441229B1 (he) |
CN (2) | CN1281588C (he) |
AP (1) | AP1002A (he) |
AR (1) | AR015595A1 (he) |
AU (1) | AU730670B2 (he) |
BG (1) | BG103828A (he) |
BR (1) | BR9810233A (he) |
CA (1) | CA2288910C (he) |
CO (1) | CO4940472A1 (he) |
CZ (1) | CZ299633B6 (he) |
DZ (1) | DZ2465A1 (he) |
EA (2) | EA002057B1 (he) |
HK (1) | HK1027808A1 (he) |
HR (1) | HRP980222B1 (he) |
ID (1) | ID22834A (he) |
IL (5) | IL132276A0 (he) |
IS (1) | IS5200A (he) |
MA (1) | MA24529A1 (he) |
NO (1) | NO314585B1 (he) |
NZ (1) | NZ338075A (he) |
OA (1) | OA11168A (he) |
PA (1) | PA8450401A1 (he) |
PE (1) | PE68699A1 (he) |
PL (1) | PL336586A1 (he) |
RS (1) | RS50118B (he) |
SK (1) | SK285991B6 (he) |
TN (1) | TNSN98053A1 (he) |
TR (1) | TR199902646T2 (he) |
WO (1) | WO1998049166A1 (he) |
Families Citing this family (138)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9423910D0 (en) * | 1994-11-26 | 1995-01-11 | Pfizer Ltd | Therapeutic agents |
IL120266A (en) | 1996-02-28 | 2005-05-17 | Pfizer | Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions |
GB9612514D0 (en) * | 1996-06-14 | 1996-08-14 | Pfizer Ltd | Novel process |
US6331543B1 (en) | 1996-11-01 | 2001-12-18 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
NZ338075A (en) | 1997-04-25 | 2000-10-27 | Pfizer Ltd | Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterase (cGMP PED5) for the treatment of sexual dysfunction |
GB9722520D0 (en) | 1997-10-24 | 1997-12-24 | Pfizer Ltd | Compounds |
TR200003039T2 (tr) * | 1998-04-20 | 2001-01-22 | Pfizer Inc. | Seksüel fonksiyon bozukluklarının tedavisi için pirazolopirimidinon cGMP PDE5 inhibitörleri |
DE19827640A1 (de) | 1998-06-20 | 1999-12-23 | Bayer Ag | 7-Alkyl- und Cycloalkyl-substituierte Imidazotriazinone |
GB9822238D0 (en) * | 1998-10-12 | 1998-12-09 | Pfizer Ltd | Process for preparation of pyrazolo[4,3-D]pyrimidin-7-ones and intermediates thereof |
GB9823102D0 (en) | 1998-10-23 | 1998-12-16 | Pfizer Ltd | Pharmaceutically active compounds |
GB9823103D0 (en) | 1998-10-23 | 1998-12-16 | Pfizer Ltd | Pharmaceutically active compounds |
GB9823101D0 (en) * | 1998-10-23 | 1998-12-16 | Pfizer Ltd | Pharmaceutically active compounds |
KR100353014B1 (ko) * | 1998-11-11 | 2002-09-18 | 동아제약 주식회사 | 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물 |
US6225315B1 (en) | 1998-11-30 | 2001-05-01 | Pfizer Inc | Method of treating nitrate-induced tolerance |
US6613768B1 (en) * | 1999-04-30 | 2003-09-02 | Lilly Icos Llc | Treatment of female arousal disorder |
NO20002097L (no) * | 1999-04-30 | 2001-10-26 | Lilly Icos Llc | Fremstillingsgjenstander |
ES2183500T3 (es) * | 1999-06-04 | 2003-03-16 | Jordanian Pharmaceutical Mfg A | Nuevos compuestos y composiciones farmaceuticas que los contienen. |
JP3145364B2 (ja) | 1999-06-04 | 2001-03-12 | ザ・ヨルダニアン・フアーマシユーテイカル・エム・エフ・ジー・アンド・メデイカル・イクイツプメント・カンパニー・リミテツド | 新規化合物及び該化合物を含有する医薬組成物 |
ES2166270B1 (es) * | 1999-07-27 | 2003-04-01 | Almirall Prodesfarma Sa | Derivados de 8-fenil-6,9-dihidro-(1,2,4,)triazolo(3,4-i)purin-5-ona. |
DE19942474A1 (de) * | 1999-09-06 | 2001-03-15 | Merck Patent Gmbh | Pyrazolo[4,3-d]pyrimidine |
TWI265925B (en) * | 1999-10-11 | 2006-11-11 | Pfizer | Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them |
GB9923968D0 (en) * | 1999-10-11 | 1999-12-15 | Pfizer Ltd | Therapeutic agents |
YU59100A (sh) * | 1999-10-11 | 2003-10-31 | Pfizer Inc. | Postupak za dobijanje pirazolo (4,3-d) pirimidin-7-ona-3-piridilsulfonil jedinjenja i njihova intermedijera |
DZ3218A1 (fr) | 1999-10-11 | 2001-04-19 | Pfizer | Pyrimidine-7-ones 5-(2-substitutees-5-heterocyclylsulphonylpyride-3-yl)-dihydropyrazolo[4,3-d] servant d'inhibiteurs de la phosphodiesterase |
US6350751B1 (en) | 1999-10-11 | 2002-02-26 | Pfizer Inc. | Therapeutic agents |
TW200400821A (en) * | 1999-11-02 | 2004-01-16 | Pfizer | Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient |
US6683081B2 (en) | 1999-12-24 | 2004-01-27 | Bayer Aktiengesellschaft | Triazolotriazinones and the use thereof |
JP2003519150A (ja) | 1999-12-24 | 2003-06-17 | バイエル アクチェンゲゼルシャフト | 新規なイミダゾ[1,3,5]トリアジノン類及びその使用 |
KR100358083B1 (ko) * | 2000-02-17 | 2002-10-25 | 에스케이케미칼주식회사 | 피롤로피리미디논 유도체와 이의 제조방법, 그리고 이의용도 |
WO2001087888A1 (en) * | 2000-05-17 | 2001-11-22 | Sk Chemicals Co., Ltd. | Pyrazolopyrimidinone derivatives, process for their preparation and their use |
KR100377782B1 (ko) * | 2000-06-23 | 2003-03-29 | 동아제약 주식회사 | 발기부전 치료에 효과를 갖는 피라졸로피리미디논화합물의 제조방법 |
EP1176142A1 (en) * | 2000-07-28 | 2002-01-30 | Pfizer Inc. | Process for the preparation of pyrazoles |
US6407259B1 (en) | 2000-07-28 | 2002-06-18 | Pfizer Inc. | Process for the preparation of pyrazoles |
JP2004506009A (ja) * | 2000-08-11 | 2004-02-26 | ファイザー・インク | インスリン抵抗性症候群の治療 |
PE20020394A1 (es) | 2000-08-18 | 2002-06-21 | Agouron Pharma | Compuestos de pirazol y composiciones farmaceuticas que los contienen, que modulan y/o inhiben la actividad de erab/hadh2 |
WO2002016364A1 (en) * | 2000-08-23 | 2002-02-28 | Lg Life Sciences Ltd. | Polyethoxylated pyrazolo pyrimidinone derivatives, process for preparation thereof and pharmaceutical compositions comprising the same for the treatment of impotence |
US6821978B2 (en) | 2000-09-19 | 2004-11-23 | Schering Corporation | Xanthine phosphodiesterase V inhibitors |
GB0025782D0 (en) * | 2000-10-20 | 2000-12-06 | Pfizer Ltd | Use of inhibitors |
US6548508B2 (en) | 2000-10-20 | 2003-04-15 | Pfizer, Inc. | Use of PDE V inhibitors for improved fecundity in mammals |
SE0004780D0 (sv) | 2000-12-22 | 2000-12-22 | Jordanian Pharmaceutical Mfg & | Novel compunds |
JP2005509038A (ja) | 2001-11-09 | 2005-04-07 | シェーリング コーポレイション | 多環式グアニン誘導体ホスホジエステラーゼv阻害剤 |
GB0129274D0 (en) * | 2001-12-06 | 2002-01-23 | Pfizer Ltd | Novel kit |
DE60237425D1 (de) | 2002-03-28 | 2010-10-07 | Univerzita Palackeho V Olomouc | PyrazoloÄ4,3-dÜpyrimidine, Verfahren zu ihrer Herstellung und therapeutische Anwendung |
GB0219961D0 (en) | 2002-08-28 | 2002-10-02 | Pfizer Ltd | Oxytocin inhibitors |
US7323462B2 (en) | 2002-12-10 | 2008-01-29 | Pfizer Inc. | Morpholine dopamine agonists |
DE60332387D1 (de) | 2002-12-13 | 2010-06-10 | Warner Lambert Co | Alpha-2-delta-ligand zur behandlung vonsymptomen der unteren harnwege |
GEP20084329B (en) | 2003-04-29 | 2008-03-25 | Pfizer Ltd | 5,7-diaminopyrazolo [4,3-d] pyrimidines useful in the treatment of hypertension |
PL2256106T3 (pl) | 2003-07-22 | 2015-08-31 | Astex Therapeutics Ltd | Związki 3,4-pochodne 1h-pirazolu i ich zastosowanie jako kinazy zależne od cyklin (cdk) i modulatory kinazy syntazy glikogenu-3 (gsk-3) |
US7291640B2 (en) | 2003-09-22 | 2007-11-06 | Pfizer Inc. | Substituted triazole derivatives as oxytocin antagonists |
US7572799B2 (en) | 2003-11-24 | 2009-08-11 | Pfizer Inc | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors |
ATE387203T1 (de) * | 2004-01-05 | 2008-03-15 | Teva Pharma | Prozesse zur herstellung von sildenafil-base und zitratsalz |
EP1779852A3 (en) * | 2004-01-05 | 2007-05-09 | Teva Pharmaceutical Industries Ltd. | Processes for the production of sildenafil base and citrate salt |
US7449462B2 (en) | 2004-01-22 | 2008-11-11 | Pfizer, Inc. | Triazole derivatives which inhibit vasopressin antagonistic activity |
US7649002B2 (en) | 2004-02-04 | 2010-01-19 | Pfizer Inc | (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists |
CA2562251C (en) | 2004-04-07 | 2009-04-28 | Pfizer Inc. | Pyrazolo'4,3-d pyrimidines |
EP2522670A1 (en) * | 2004-04-07 | 2012-11-14 | Takeda Pharmaceutical Company Limited | Heterocyclic CRF receptor antagonists |
EP1786428B1 (en) | 2004-08-17 | 2012-05-16 | The Johns Hopkins University | Pde5 inhibitor compositions and methods for treating cardiac indications |
TWI367098B (en) * | 2004-12-23 | 2012-07-01 | Kowa Co | Treating agent for glaucoma |
US8404718B2 (en) | 2005-01-21 | 2013-03-26 | Astex Therapeutics Limited | Combinations of pyrazole kinase inhibitors |
AR054425A1 (es) | 2005-01-21 | 2007-06-27 | Astex Therapeutics Ltd | Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico. |
US7618972B2 (en) | 2005-03-21 | 2009-11-17 | Pfizer Inc | Substituted triazole derivatives as oxytocin antagonists |
US8648100B2 (en) | 2005-04-19 | 2014-02-11 | Takeda Gmbh | Roflumilast for the treatment of pulmonary hypertension |
US8506934B2 (en) | 2005-04-29 | 2013-08-13 | Robert I. Henkin | Methods for detection of biological substances |
AU2006245416B2 (en) | 2005-05-12 | 2012-02-23 | Pfizer Inc. | Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide |
ZA200804550B (en) | 2005-11-09 | 2009-08-26 | Combinatorx Inc | Methods, compositions, and kits for the treatment of medical conditions |
AU2006327882A1 (en) * | 2005-12-20 | 2007-06-28 | Pfizer Products Inc. | Pharmaceutical combination for the treatment of LUTS comprising a PDE5 inhibitor and a muscarinic antagonist |
GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
WO2008095136A2 (en) | 2007-01-31 | 2008-08-07 | Henkin Robert I | Methods for detection of biological substances |
US8580801B2 (en) | 2008-07-23 | 2013-11-12 | Robert I. Henkin | Phosphodiesterase inhibitor treatment |
CN101747282A (zh) | 2008-12-10 | 2010-06-23 | 上海特化医药科技有限公司 | 一类含有嘧啶酮苯基的化合物、其药物组合物及其制备方法和用途 |
EP2379076B1 (en) | 2008-12-23 | 2014-11-12 | The Trustees of Columbia University in the City of New York | Phosphodiesterase inhibitors and uses thereof |
GB0903493D0 (en) | 2009-02-27 | 2009-04-08 | Vantia Ltd | New compounds |
TWI462739B (zh) | 2010-11-02 | 2014-12-01 | Univ Kaohsiung Medical | Sildenafil-同族物四級銨哌嗪鹽類之製備及醫療用途 |
ES2775125T3 (es) | 2010-11-03 | 2020-07-23 | Dow Agrosciences Llc | Composiciones plaguicidas y procedimientos relacionados |
CN102134242B (zh) * | 2011-01-21 | 2013-08-28 | 浙江大德药业集团有限公司 | 一种用于治疗阳痿的快速长效的化合物 |
EP2753332B1 (en) * | 2011-09-09 | 2017-02-15 | SK Chemicals Co., Ltd. | Mridenafil for reducing skin wrinkles |
KR102006039B1 (ko) | 2011-10-26 | 2019-07-31 | 다우 아그로사이언시즈 엘엘씨 | 살충 조성물 및 그와 관련된 방법 |
US9402877B2 (en) | 2011-11-04 | 2016-08-02 | Xion Pharmaceuticals Corporation | Methods and compositions for oral administration of melanocortin receptor agonist compounds |
EP2804603A1 (en) | 2012-01-10 | 2014-11-26 | President and Fellows of Harvard College | Beta-cell replication promoting compounds and methods of their use |
WO2013109738A1 (en) | 2012-01-17 | 2013-07-25 | The Trustees Of Columbia University In The City Of New York | Novel phosphodiesterase inhibitors and uses thereof |
RU2627654C2 (ru) | 2012-04-27 | 2017-08-09 | ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи | Пестицидные композиции и относящиеся к ним способы |
US9282739B2 (en) | 2012-04-27 | 2016-03-15 | Dow Agrosciences Llc | Pesticidal compositions and processes related thereto |
US9708288B2 (en) | 2012-04-27 | 2017-07-18 | Dow Agrosciences Llc | Pesticidal compositions and processes related thereto |
WO2014055801A1 (en) | 2012-10-05 | 2014-04-10 | Henkin Robert I | Phosphodiesterase inhibitors for treating taste and smell disorders |
EP3470070B1 (en) | 2012-12-21 | 2021-04-28 | Mayo Foundation for Medical Education and Research | Methods and materials for treating calcific aortic valve stenosis |
CN103265479B (zh) * | 2013-06-14 | 2017-12-08 | 南开大学 | 一种6‑氯甲基烟酸叔丁酯的合成方法 |
US10899756B2 (en) | 2013-07-17 | 2021-01-26 | The Trustees Of Columbia University In The City Of New York | Phosphodiesterase inhibitors and uses thereof |
MX2016004942A (es) | 2013-10-17 | 2016-06-28 | Dow Agrosciences Llc | Procesos para la preparacion de compuestos plaguicidas. |
EP3057431A4 (en) | 2013-10-17 | 2017-04-05 | Dow AgroSciences LLC | Processes for the preparation of pesticidal compounds |
CN105636443A (zh) | 2013-10-17 | 2016-06-01 | 美国陶氏益农公司 | 制备杀虫化合物的方法 |
WO2015058023A1 (en) | 2013-10-17 | 2015-04-23 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
KR20160074543A (ko) | 2013-10-17 | 2016-06-28 | 다우 아그로사이언시즈 엘엘씨 | 살충성 화합물의 제조 방법 |
EP3057429A4 (en) | 2013-10-17 | 2017-08-09 | Dow AgroSciences LLC | Processes for the preparation of pesticidal compounds |
MX2016004940A (es) | 2013-10-17 | 2016-06-28 | Dow Agrosciences Llc | Proceso para la preparacion de compuestos plaguicidas. |
WO2015061147A1 (en) | 2013-10-22 | 2015-04-30 | Dow Agrosciences Llc | Synergistic pesticidal compositions and related methods |
EP3060049A4 (en) | 2013-10-22 | 2017-04-05 | Dow AgroSciences LLC | Synergistic pesticidal compositions and related methods |
EP3060047A4 (en) | 2013-10-22 | 2017-04-26 | Dow AgroSciences, LLC | Pesticidal compositions and related methods |
TW201519773A (zh) | 2013-10-22 | 2015-06-01 | Dow Agrosciences Llc | 協同性殺蟲組成物及相關方法(五) |
JP2016539930A (ja) | 2013-10-22 | 2016-12-22 | ダウ アグロサイエンシィズ エルエルシー | 農薬組成物および関連する方法 |
NZ719968A (en) | 2013-10-22 | 2017-05-26 | Dow Agrosciences Llc | Pesticidal compositions and related methods |
JP2016535026A (ja) | 2013-10-22 | 2016-11-10 | ダウ アグロサイエンシィズ エルエルシー | 相乗的有害生物防除組成物および関連する方法 |
BR112016008801B1 (pt) | 2013-10-22 | 2019-12-17 | Dow Agrosciences Llc | composições pesticidas |
EP3060054A4 (en) | 2013-10-22 | 2017-04-05 | Dow AgroSciences LLC | Synergistic pesticidal compositions and related methods |
MX2016005316A (es) | 2013-10-22 | 2017-03-01 | Dow Agrosciences Llc | Composiciones pesticidas sinergicas y metodos relacionados. |
EP3060051A4 (en) | 2013-10-22 | 2017-04-05 | Dow AgroSciences LLC | Synergistic pesticidal compositions and related methods |
NZ719688A (en) | 2013-10-22 | 2017-06-30 | Dow Agrosciences Llc | Pesticidal compositions and related methods |
JP2016536304A (ja) | 2013-10-22 | 2016-11-24 | ダウ アグロサイエンシィズ エルエルシー | 相乗的有害生物防除組成物および関連する方法 |
JP2016538265A (ja) | 2013-10-22 | 2016-12-08 | ダウ アグロサイエンシィズ エルエルシー | 相乗的有害生物防除組成物および関連する方法 |
JP2016534076A (ja) | 2013-10-22 | 2016-11-04 | ダウ アグロサイエンシィズ エルエルシー | 相乗的有害生物防除組成物および関連する方法 |
WO2015061161A1 (en) | 2013-10-22 | 2015-04-30 | Dow Agrosciences Llc | Pesticidal compositions and related methods |
RU2016119560A (ru) | 2013-10-22 | 2017-11-28 | ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи | Синергетические пестицидные композиции и относящиеся к ним способы |
WO2015126944A1 (en) | 2014-02-18 | 2015-08-27 | Henkin Robert I | Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell |
KR20170036677A (ko) | 2014-07-31 | 2017-04-03 | 다우 아그로사이언시즈 엘엘씨 | 3-(3-클로로-1h-피라졸-1-일)피리딘의 제조 방법 |
KR20170038785A (ko) | 2014-07-31 | 2017-04-07 | 다우 아그로사이언시즈 엘엘씨 | 3-(3-클로로-1h-피라졸-1-일)피리딘의 제조 방법 |
BR112017000565A2 (pt) | 2014-07-31 | 2017-11-07 | Dow Agrosciences Llc | processo para a preparação de 3-(3-cloro-1h-pirazol-1-il)piridina |
US9024031B1 (en) | 2014-08-19 | 2015-05-05 | Dow Agrosciences Llc | Process for the preparation of 3-(3-chloro-1H-pyrazol-1-yl)pyridine |
CN107074775A (zh) | 2014-09-12 | 2017-08-18 | 美国陶氏益农公司 | 3‑(3‑氯‑1h‑吡唑‑1‑基)吡啶的制备方法 |
MX2017003646A (es) * | 2014-09-17 | 2017-07-13 | Intra Cellular Therapies Inc | Compuestos y metodos. |
WO2016145614A1 (en) | 2015-03-17 | 2016-09-22 | Merck Sharp & Dohme Corp. | Triazolyl pyrimidinone compounds as pde2 inhibitors |
WO2016183741A1 (en) | 2015-05-15 | 2016-11-24 | Merck Sharp & Dohme Corp. | Pyrimidinone amide compounds as pde2 inhibitors |
WO2018049214A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
CN115819417A (zh) | 2016-09-09 | 2023-03-21 | 因赛特公司 | 作为hpk1调节剂的吡唑并吡啶衍生物及其用于治疗癌症的用途 |
AR109595A1 (es) | 2016-09-09 | 2018-12-26 | Incyte Corp | Compuestos de pirazolopirimidina y usos de estos como inhibidores de hpk1 |
CN110325036B (zh) | 2016-12-29 | 2021-10-26 | 美国陶氏益农公司 | 用于制备杀虫化合物的方法 |
JP2020503336A (ja) | 2016-12-29 | 2020-01-30 | ダウ アグロサイエンシィズ エルエルシー | 殺有害生物化合物の調製方法 |
US20180228786A1 (en) | 2017-02-15 | 2018-08-16 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
WO2019051199A1 (en) | 2017-09-08 | 2019-03-14 | Incyte Corporation | 6-CYANO-INDAZOLE COMPOUNDS AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) MODULATORS |
WO2019164846A1 (en) | 2018-02-20 | 2019-08-29 | Incyte Corporation | N-(phenyl)-2-(phenyl)pyrimidine-4-carboxamide derivatives and related compounds as hpk1 inhibitors for treating cancer |
US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
WO2019164847A1 (en) | 2018-02-20 | 2019-08-29 | Incyte Corporation | Indazole compounds and uses thereof |
US11299473B2 (en) | 2018-04-13 | 2022-04-12 | Incyte Corporation | Benzimidazole and indole compounds and uses thereof |
US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
MA53726A (fr) | 2018-09-25 | 2022-05-11 | Incyte Corp | Composés pyrazolo[4,3-d]pyrimidine en tant que modulateurs des alk2 et/ou fgfr |
JP2022509815A (ja) * | 2018-11-28 | 2022-01-24 | トパデュール ファルマ アーゲー | 新規の二重作用型可溶性グアニル酸シクラーゼ活性化剤およびホスホジエステラーゼ阻害剤とその使用法 |
US11066394B2 (en) | 2019-08-06 | 2021-07-20 | Incyte Corporation | Solid forms of an HPK1 inhibitor |
CN113493459B (zh) * | 2020-04-07 | 2022-12-13 | 广州白云山医药集团股份有限公司白云山制药总厂 | Pde5抑制剂化合物及其制备方法和应用 |
CN113754612B (zh) * | 2021-10-26 | 2023-09-26 | 山东安舜制药有限公司 | 一种西地那非中间体的制备方法 |
CN115785101B (zh) * | 2022-11-23 | 2023-10-13 | 西安市食品药品检验所 | 一种含有苯基哌嗪结构的那非类化合物及其制备方法 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3992441A (en) | 1972-12-26 | 1976-11-16 | Pfizer Inc. | Sulfamylbenzoic acids |
DE3420985A1 (de) | 1983-10-15 | 1985-04-25 | Bayer Ag, 5090 Leverkusen | Substituierte 5-acylamino-1-phenylpyrazole |
US4871843A (en) | 1983-10-18 | 1989-10-03 | Dropic-Societe Civile De Gestion De Droits De Propriete Industrielle | Cyclic benzenesulfonamides, process for their preparation and their use as active substance of pharmaceutical compositions |
US4663326A (en) | 1985-04-04 | 1987-05-05 | Warner-Lambert Company | Pyrazolo[4,3-d]pyrimidine-5,7-(4H,6H)dione or -5-thione-7-one analogs |
US4666908A (en) | 1985-04-05 | 1987-05-19 | Warner-Lambert Company | 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use |
US5075310A (en) | 1988-07-01 | 1991-12-24 | Smith Kline & French Laboratories, Ltd. | Pyrimidone derivatives as bronchodilators |
GB8817651D0 (en) | 1988-07-25 | 1988-09-01 | Smith Kline French Lab | Chemical compounds |
GB8827988D0 (en) | 1988-11-30 | 1989-01-05 | Smith Kline French Lab | Chemical compounds |
GB8928346D0 (en) | 1989-12-15 | 1990-02-21 | Smith Kline French Lab | Chemical compounds |
US5250534A (en) | 1990-06-20 | 1993-10-05 | Pfizer Inc. | Pyrazolopyrimidinone antianginal agents |
GB9013750D0 (en) * | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
GB9114760D0 (en) | 1991-07-09 | 1991-08-28 | Pfizer Ltd | Therapeutic agents |
GB9119704D0 (en) | 1991-09-14 | 1991-10-30 | Pfizer Ltd | Therapeutic agents |
GB9121028D0 (en) | 1991-10-03 | 1991-11-13 | Pfizer Ltd | Therapeutic agents |
GB9126260D0 (en) | 1991-12-11 | 1992-02-12 | Pfizer Ltd | Therapeutic agents |
GB9202238D0 (en) | 1992-02-03 | 1992-03-18 | Wellcome Found | Compounds |
US5294612A (en) | 1992-03-30 | 1994-03-15 | Sterling Winthrop Inc. | 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof |
US5734053A (en) | 1992-06-26 | 1998-03-31 | Pfizer Inc | Purinone antianginal agents |
GB9213623D0 (en) | 1992-06-26 | 1992-08-12 | Pfizer Ltd | Therapeutic agents |
JP2657760B2 (ja) | 1992-07-15 | 1997-09-24 | 小野薬品工業株式会社 | 4−アミノキナゾリン誘導体およびそれを含有する医薬品 |
GB9218322D0 (en) | 1992-08-28 | 1992-10-14 | Pfizer Ltd | Therapeutic agents |
GB9311920D0 (en) * | 1993-06-09 | 1993-07-28 | Pfizer Ltd | Therapeutic agents |
GB9315017D0 (en) | 1993-07-20 | 1993-09-01 | Glaxo Lab Sa | Chemical compounds |
GB9423910D0 (en) * | 1994-11-26 | 1995-01-11 | Pfizer Ltd | Therapeutic agents |
GB9423911D0 (en) | 1994-11-26 | 1995-01-11 | Pfizer Ltd | Therapeutic agents |
US5656629A (en) | 1995-03-10 | 1997-08-12 | Sanofi Winthrop, Inc. | 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof |
WO1996028448A1 (en) | 1995-03-10 | 1996-09-19 | Sanofi Winthrop, Inc. | 6-ARYL PYRAZOLO[3,4-d]PYRIMIDIN-4-ONES AND COMPOSITIONS AND METHODS OF USE THEREOF |
GB9612514D0 (en) | 1996-06-14 | 1996-08-14 | Pfizer Ltd | Novel process |
NZ338075A (en) | 1997-04-25 | 2000-10-27 | Pfizer Ltd | Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterase (cGMP PED5) for the treatment of sexual dysfunction |
TR200003039T2 (tr) | 1998-04-20 | 2001-01-22 | Pfizer Inc. | Seksüel fonksiyon bozukluklarının tedavisi için pirazolopirimidinon cGMP PDE5 inhibitörleri |
US6087368A (en) | 1998-06-08 | 2000-07-11 | Bristol-Myers Squibb Company | Quinazolinone inhibitors of cGMP phosphodiesterase |
-
1998
- 1998-04-10 NZ NZ338075A patent/NZ338075A/xx unknown
- 1998-04-10 WO PCT/EP1998/002257 patent/WO1998049166A1/en active Application Filing
- 1998-04-10 IL IL13227698A patent/IL132276A0/xx active IP Right Grant
- 1998-04-10 EP EP98924132A patent/EP0977756A1/en not_active Withdrawn
- 1998-04-10 AU AU76445/98A patent/AU730670B2/en not_active Ceased
- 1998-04-10 ID IDW991261A patent/ID22834A/id unknown
- 1998-04-10 RS YUP-524/99A patent/RS50118B/sr unknown
- 1998-04-10 TR TR1999/02646T patent/TR199902646T2/xx unknown
- 1998-04-10 EA EA199900866A patent/EA002057B1/ru not_active IP Right Cessation
- 1998-04-10 CZ CZ0376799A patent/CZ299633B6/cs not_active IP Right Cessation
- 1998-04-10 CA CA002288910A patent/CA2288910C/en not_active Expired - Fee Related
- 1998-04-10 PL PL98336586A patent/PL336586A1/xx not_active IP Right Cessation
- 1998-04-10 KR KR10-1999-7009887A patent/KR100441229B1/ko not_active IP Right Cessation
- 1998-04-10 BR BR9810233-8A patent/BR9810233A/pt active Search and Examination
- 1998-04-10 KR KR10-2002-7006773A patent/KR100390612B1/ko not_active IP Right Cessation
- 1998-04-10 CN CNB2004100685255A patent/CN1281588C/zh not_active Expired - Fee Related
- 1998-04-10 CN CNB988044765A patent/CN1188415C/zh not_active Expired - Fee Related
- 1998-04-10 SK SK1446-99A patent/SK285991B6/sk not_active IP Right Cessation
- 1998-04-10 US US09/402,229 patent/US6723719B1/en not_active Expired - Fee Related
- 1998-04-10 EA EA200100504A patent/EA004315B1/ru not_active IP Right Cessation
- 1998-04-10 JP JP54654398A patent/JP3563078B2/ja not_active Expired - Fee Related
- 1998-04-20 PA PA19988450401A patent/PA8450401A1/es unknown
- 1998-04-22 DZ DZ980076A patent/DZ2465A1/xx active
- 1998-04-22 TN TNTNSN98053A patent/TNSN98053A1/fr unknown
- 1998-04-22 MA MA25040A patent/MA24529A1/fr unknown
- 1998-04-23 AR ARP980101889A patent/AR015595A1/es unknown
- 1998-04-23 AP APAP/P/1998/001228A patent/AP1002A/en active
- 1998-04-23 CO CO98022516A patent/CO4940472A1/es unknown
- 1998-04-24 PE PE1998000312A patent/PE68699A1/es not_active Application Discontinuation
- 1998-04-24 HR HR980222A patent/HRP980222B1/xx not_active IP Right Cessation
-
1999
- 1999-09-28 IS IS5200A patent/IS5200A/is unknown
- 1999-10-07 IL IL132276A patent/IL132276A/he not_active IP Right Cessation
- 1999-10-22 BG BG103828A patent/BG103828A/xx unknown
- 1999-10-22 OA OA9900234A patent/OA11168A/en unknown
- 1999-10-25 NO NO19995211A patent/NO314585B1/no not_active IP Right Cessation
-
2000
- 2000-11-03 HK HK00107029A patent/HK1027808A1/xx not_active IP Right Cessation
-
2003
- 2003-08-28 IL IL157645A patent/IL157645A/he not_active IP Right Cessation
- 2003-08-28 IL IL157646A patent/IL157646A/he not_active IP Right Cessation
- 2003-08-28 IL IL157647A patent/IL157647A/he not_active IP Right Cessation
-
2004
- 2004-03-03 JP JP2004059879A patent/JP4036836B2/ja not_active Expired - Fee Related
- 2004-03-23 US US10/808,027 patent/US6916927B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6723719B1 (en) | Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3′,5′—monophosphate phosphodiesterase (cGMP PDE5) for the treatment of sexual dysfunction | |
US6235742B1 (en) | 5-substituted pyrazolo[4,3-D]pyrimidin-7-ones | |
DE60219292T2 (de) | Pyrazolderivate zur behandlung von hiv | |
JP3721023B2 (ja) | 性的機能障害の治療用のピラゾロピリミジノンcGMPPDE5阻害剤 | |
KR101585840B1 (ko) | 글루카곤 수용체 조절자 | |
US6407114B1 (en) | Pyrazolopyrimidinone CGMP PDE5 inhibitors for the treatment of sexual dysfunction | |
EP1123296B1 (en) | PYRAZOLOPYRIMIDINONE cGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | |
BG106568A (bg) | 5-(2-заместени-5-хетероциклилсулфонилпирид-3-ил)-дихидропиразоло[4,3-d]пиримидин-7-они като фосфодиестеразни инхибитори | |
US6333330B1 (en) | Pyrazolopyrimidinone CGMP PDE5 inhibitors for the treatment of sexual dysfunction | |
TW524805B (en) | Pyrazolo[4,3-d]pyrimidine-7-one compounds having the effect of inhibiting phosphodiesterase (PDE-5) and the preparation processes, intermediates and pharmaceutical compositions or veterinary formulations thereof | |
MXPA99009762A (en) | PYRAZOLOPYRIMIDINONES WHICH INHIBIT TYPE 5 CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE (cGMP PDE5) FOR THE TREATMENT OF SEXUAL DYSFUNCTION | |
MXPA01004009A (en) | PYRAZOLOPYRIMIDINONE cGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | |
MXPA00010388A (en) | Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |